nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,intervention_type,intervention_name,description,intervention_count,status,facility_name,city,state,zip,country,site_count
NCT04244591,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-23,NA,NA,2020-02-12,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-13,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"December 25, 2020",Anticipated,2020-12-25,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,Steroids-SARI,,Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial",Recruiting,NA,Phase 2/Phase 3,80,Anticipated,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:28:22Z,2020-04-01T09:28:22Z,Drug|Other,methylprednisolone therapy|Standard care,Methylprednisolone 40 mg q12h for 5 days|Standard care,2,Recruiting,"Medical ICU,Peking Union Medical College Hospital",Beijing,Beijing,010,China,1
NCT04252118,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-27,NA,NA,2020-02-25,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-26,Actual,"January 27, 2020",Actual,2020-01-27,February 2020,2020-02-29,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:27:23Z,2020-04-01T09:27:23Z,Biological,MSCs,"3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).",1,Recruiting,Beijing 302 Military Hospital of China,Beijing,,100039,China,1
NCT04251871,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-28,NA,NA,2020-01-30,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-30,2020-02-05,Actual,"January 22, 2020",Actual,2020-01-22,January 2020,2020-01-31,"January 22, 2021",Anticipated,2021-01-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,NA,,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,N/A,150,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:27:26Z,2020-04-01T09:27:26Z,Drug|Drug,"Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.",2,Recruiting,"The Fifth Medical Center, General Hospital of PLA",Beijing,Beijing,100039,China,1
NCT04252274,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-29,NA,NA,2020-03-03,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"January 30, 2020",Actual,2020-01-30,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,DACO-nCoV,,Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV,Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:27:22Z,2020-04-01T09:27:22Z,Drug,Darunavir and Cobicistat,"Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments",1,Recruiting|Recruiting,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
NCT04252885,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-30,NA,NA,2020-01-31,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-31,2020-02-05,Actual,"January 28, 2020",Anticipated,2020-01-28,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Recruiting,NA,Phase 4,125,Anticipated,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:27:18Z,2020-04-01T09:27:18Z,Drug|Drug,Lopinavir and Ritonavir Tablets|Arbidol,As indicated in arm/group descriptions|As indicated in arm/group descriptions,2,Recruiting,Guangzhou Eighth People's Hospital,Guangzhou,Guangdong,510060,China,1
NCT04251767,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-30,NA,NA,2020-03-13,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"February 5, 2020",Anticipated,2020-02-05,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Washed Microbiota Transplantation for Patients With 2019-nCoV Infection,"Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study",Withdrawn,NA,N/A,0,Actual,The Second Hospital of Nanjing Medical University,,2,NA,Follow new disciplines on disease control from government,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-01T09:27:26Z,2020-04-01T09:27:26Z,Other|Other,washed microbiota transplantation|placebo,"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.
Dose and frequency: 5u, once.|Placebo (edible suspension of the same color as the washed microbiota suspensionï¼Œ5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
Dose and frequency: 5u, once.",2,,"Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University",Nanjing,Jiangsu,210011,China,1
NCT04257656,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-31,NA,NA,2020-02-20,2020-02-03,2020-02-06,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 6, 2020",Actual,2020-02-06,February 2020,2020-02-29,"May 1, 2020",Anticipated,2020-05-01,"April 3, 2020",Anticipated,2020-04-03,NA,Interventional,NA,,Severe 2019-nCoV Remdesivir RCT,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease.",Recruiting,NA,Phase 3,453,Anticipated,Capital Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:26:36Z,2020-04-01T09:26:36Z,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,Recruiting,Bin Cao,Beijing,Beijing,100029,China,1
NCT04252664,"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-31,NA,NA,2020-02-20,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"February 12, 2020",Actual,2020-02-12,February 2020,2020-02-29,"April 27, 2020",Anticipated,2020-04-27,"April 10, 2020",Anticipated,2020-04-10,NA,Interventional,NA,,Mild/Moderate 2019-nCoV Remdesivir RCT,"A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease.",Recruiting,NA,Phase 3,308,Anticipated,Capital Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:27:20Z,2020-04-01T09:27:20Z,Drug|Drug,Remdesivir|Remdesivir placebo,"RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",2,Recruiting,Jin Yin-tan hospital,Wu Han,Hubei,100013,China,1
NCT04263402,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:25:53Z,2020-04-01T09:25:53Z,Drug|Drug,Methylprednisolone|Methylprednisolone,"Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04255017,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:27:04Z,2020-04-01T09:27:04Z,Drug|Drug|Drug,Abidol hydrochloride|Oseltamivir|Lopinavir/ritonavir,"Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04254874,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:27:04Z,2020-04-01T09:27:04Z,Drug|Drug,Abidol hydrochloride|Abidol Hydrochloride combined with Interferon atomization,"0.2g once, 3 times a day,two weeks|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-Î±-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks",2,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04264533,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-04,NA,NA,2020-03-06,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-10,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial,Recruiting,NA,Phase 2,140,Anticipated,Zhongnan Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:25:41Z,2020-04-01T09:25:41Z,Drug|Drug,VC|Sterile Water for Injection,12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.,2,Recruiting,Zhongnan Hospital of Wuhan University,Wuhan,Hubei,430000,China,1
NCT04261270,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-04,NA,NA,2020-03-14,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:26:11Z,2020-04-01T09:26:11Z,Drug|Drug|Drug,ASC09F+Oseltamivir|Ritonavir+Oseltamivir|Oseltamivir,"ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day|75mg ,once a day",3,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04275245,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,"February 3, 2020",Actual,2020-02-03,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:24:15Z,2020-04-01T09:24:15Z,Drug,Meplazumab for Injection,humanized MAb against CD147,1,Recruiting,Tangdu Hospital,Xi'an,Shaanxi,710032,China,1
NCT04261907,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-10,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,"A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection",Not yet recruiting,NA,N/A,160,Anticipated,First Affiliated Hospital of Zhejiang University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:26:07Z,2020-04-01T09:26:07Z,Drug|Drug,ASC09/ritonavir group|lopinavir/ritonavir group,"ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04260594,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-07,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Not yet recruiting,NA,Phase 4,380,Anticipated,Ruijin Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:26:15Z,2020-04-01T09:26:15Z,Drug|Other,Arbidol|basic treatment,"Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days|basic treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04331613,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-06,NA,NA,2020-03-31,2020-03-31,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"January 27, 2020",Actual,2020-01-27,January 2020,2020-01-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,9,Anticipated,Chinese Academy of Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:12:20Z,2020-04-03T09:12:20Z,Biological,CAStem,CAStem will be administered intravenously.,1,Recruiting,"Beijing YouAn Hospital, Capital Medical University",Beijing,"Beijing, China",100000,China,1
NCT04261517,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-06,NA,NA,2020-03-22,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"February 6, 2020",Actual,2020-02-06,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ),Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ),Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:22:53Z,2020-04-03T09:22:53Z,Drug,Hydroxychloroquine,"Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments",1,|,Shanghai Public Health Clinical Center|Shanghai Public Health Clinical Center,Shanghai|Shanghai,Shanghai|Shanghai,201508|,China|China,2
NCT04269525,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-07,NA,NA,2020-02-12,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-17,Actual,"February 6, 2020",Actual,2020-02-06,February 2020,2020-02-29,"September 30, 2020",Anticipated,2020-09-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection,Recruiting,NA,Phase 2,10,Anticipated,Zhongnan Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:25:03Z,2020-04-01T09:25:03Z,Biological,UC-MSCs,"After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.",1,Recruiting,Zhongnan Hospital of Wuhan University,Wuhan,Hubei,430000,China,1
NCT04268537,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-08,NA,NA,2020-02-12,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-02-12,2020-02-13,Actual,"February 10, 2020",Anticipated,2020-02-10,February 2020,2020-02-29,"October 31, 2020",Anticipated,2020-10-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Immunoregulatory Therapy for 2019-nCoV,Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients,Not yet recruiting,NA,Phase 2,120,Anticipated,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:25:10Z,2020-04-01T09:25:10Z,Drug|Drug|Other,PD-1 blocking antibody+standard treatment|Thymosin+standard treatment|standard treatment,"After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection|Standard treatment is according to the protocol of treatment of 2019-nCoV infection",3,NA,NA,NA,NA,NA,NA,NA
NCT04264858,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-08,NA,NA,2020-03-13,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"March 17, 2020",Anticipated,2020-03-17,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients,Not yet recruiting,NA,N/A,10,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:25:37Z,2020-04-01T09:25:37Z,Drug|Drug,Immunoglobulin of cured patients|Î³-Globulin,"0.2g/kg, ivdrip, once a day, for 3 days|0.2g/kg, ivdrip, once a day, for 3 days",2,,"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430022,China,1
NCT04282902,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:17Z,2020-04-01T09:23:17Z,Drug,pirfenidone,"Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer",1,Recruiting,Tongji hospital affiliated to huazhong university of science and technology,Wuhan,Hubei,,China,1
NCT04276688,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-11,NA,NA,2020-02-26,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-26,2020-02-28,Actual,"February 10, 2020",Actual,2020-02-10,February 2020,2020-02-29,"July 31, 2022",Anticipated,2022-07-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Recruiting,NA,Phase 2,70,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:24:05Z,2020-04-01T09:24:05Z,Drug|Drug|Drug,Lopinavir/ritonavir|Ribavirin|Interferon Beta-1B,400mg/100mg twice daily for 14 days|400mg twice daily for 14 days|0.25mg subcutaneous injection alternate day for 3 days,3,Recruiting,"University of Hong Kong, Queen Mary Hospital",Hong Kong,,,Hong Kong,1
NCT04280224,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-13,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 20, 2020",Anticipated,2020-02-20,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,NK Cells Treatment for Novel Coronavirus Pneumonia,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:35Z,2020-04-01T09:23:35Z,Biological,NK Cells,twice a week of NK cells (0.1-2*10E7 cells/kg body weight),1,Recruiting,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,453000,China,1
NCT04304313,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-03-14,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 9, 2020",Actual,2020-02-09,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"March 1, 2020",Actual,2020-03-01,NA,Interventional,NA,,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:20:35Z,2020-04-01T09:20:35Z,Drug,Sildenafil citrate tablets,0.1g/day for 14 days,1,Recruiting,Department and Institute of Infectious Disease,Wuhan,Hubei,430030,China,1
NCT04275414,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP),Recruiting,NA,Phase 2/Phase 3,20,Anticipated,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:24:13Z,2020-04-01T09:24:13Z,Drug,Bevacizumab Injection,"Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip â‰¥90min",1,Recruiting,Qilu Hospital of Shandong University,Jinan,Shandong,250012,China,1
NCT04273646,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 16, 2020",Anticipated,2020-02-16,February 2020,2020-02-29,"February 15, 2022",Anticipated,2022-02-15,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia,Not yet recruiting,NA,N/A,48,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:24:27Z,2020-04-01T09:24:27Z,Biological|Drug,UC-MSCs|Placebo,"4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).",2,,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430000,China,1
NCT04273581,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 18, 2020",Anticipated,2020-02-18,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,40,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:24:28Z,2020-04-01T09:24:28Z,Drug|Drug,placebo|Thalidomide,100mg/dï¼Œqnï¼Œfor 14 days.|100mg/dï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04273529,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-14,NA,NA,2020-02-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 20, 2020",Anticipated,2020-02-20,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2,100,Anticipated,First Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:24:28Z,2020-04-01T09:24:28Z,Drug|Drug,thalidomide|placebo,100mgï¼Œpoï¼Œqnï¼Œfor 14 days.|100mgï¼Œpoï¼Œqnï¼Œfor 14 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04273763,"ClinicalTrials.gov processed this data on April 01, 2020",2020-02-14,NA,NA,2020-03-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"February 16, 2020",Actual,2020-02-16,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Enrolling by invitation,NA,N/A,60,Anticipated,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:23:21Z,2020-04-02T09:23:21Z,Drug|Drug|Drug,Bromhexine Hydrochloride Tablets|Arbidol Hydrochloride Granules|Recombinant Human Interferon Î±2b Spray,Bromhexine Hydrochloride Tablets|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.,3,,The Second AffIliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,325000,China,1
NCT04293887,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-15,NA,NA,2020-03-02,2020-03-02,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-02,2020-03-03,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Efficacy and Safety of IFN-Î±2Î² in the Treatment of Novel Coronavirus Patients,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon Î±1Î² in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",Not yet recruiting,NA,Early Phase 1,328,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:21:54Z,2020-04-01T09:21:54Z,Drug,Recombinant human interferon Î±1Î²,Saline needle 2ml + recombinant human interferon Î±1Î²10ug bid nebulization inhalation,1,NA,NA,NA,NA,NA,NA,NA
NCT04279197,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-15,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,,Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu,"A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV",Recruiting,NA,Phase 2,136,Anticipated,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:44Z,2020-04-01T09:23:44Z,Drug|Drug,N-acetylcysteine+ Fuzheng Huayu Tablet|N-acetylcysteine+Placebo,The subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks.|The subjects will be taking 1 N-acetylcysteine capcule and 4 Placebo tablets three times a day for 24 weeks.,2,Recruiting,Shuguang Hospital,Shanghai,Shanghai,201203,China,1
NCT04273321,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-15,NA,NA,2020-03-31,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"February 14, 2020",Actual,2020-02-14,March 2020,2020-03-31,"May 30, 2020",Anticipated,2020-05-30,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Recruiting,NA,N/A,400,Anticipated,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-03T09:22:27Z,2020-04-03T09:22:27Z,Drug,Methylprednisolone,Methylprednisolone 1mg/kg/day ivgtt for 7 days.,1,Terminated|Terminated|Recruiting|Terminated|Terminated|Terminated|Recruiting,Hubei province hospital of integrated Chinese & Western Medicine|Yichang first people's Hospital|Beijing YouAn Hospital|Renmin Hospital of Wuhan University|Tianyou Hospital Affiliated to Wuhan University of science and technology|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology|the first peopel hospital of Xiangyang,Wuhan|Yichang|Beijing|Wuhan|Wuhan|Wuhan|Xiangyang,Hubei|Hubei|||||,||||||,China|China|China|China|China|China|China,7
NCT04276987,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-16,NA,NA,2020-02-21,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Not yet recruiting,NA,Phase 1,30,Anticipated,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2020-04-01T09:24:02Z,2020-04-01T09:24:02Z,Biological,MSCs-derived exosomes,"5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).",1,NA,NA,NA,NA,NA,NA,NA
NCT04276896,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:24:03Z,2020-04-01T09:24:03Z,Biological,Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,"Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.",1,Recruiting|Recruiting|Recruiting,Shenzhen Geno-immune Medical Institute|Shenzhen Second People's Hospital|Shenzhen Third People's Hospital,Shenzhen|Shenzhen|Shenzhen,Guangdong|Guangdong|Guangdong,518000|518000|518000,China|China|China,3
NCT04275388,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-17,NA,NA,2020-02-18,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-18,2020-02-19,Actual,"February 14, 2020",Anticipated,2020-02-14,February 2020,2020-02-29,"December 14, 2021",Anticipated,2021-12-14,"May 14, 2020",Anticipated,2020-05-14,NA,Interventional,NA,,Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia,"A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia",Not yet recruiting,NA,N/A,348,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:24:13Z,2020-04-01T09:24:13Z,Drug|Drug,"Xiyanping injection|Lopinavir / ritonavir, alpha-interferon nebulization","Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
NCT04285190,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-19,NA,NA,2020-02-24,2020-02-24,2020-02-26,Actual,NA,NA,NA,NA,NA,NA,2020-02-24,2020-02-26,Actual,"February 26, 2020",Anticipated,2020-02-26,February 2020,2020-02-29,"September 15, 2020",Anticipated,2020-09-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,NA,,The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19,A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,N/A,120,Anticipated,"Tasly Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share,2020-04-01T09:23:00Z,2020-04-01T09:23:00Z,Drug,T89,"The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.",1,NA,NA,NA,NA,NA,NA,NA
NCT04278963,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-19,NA,NA,2020-03-15,2020-02-19,2020-02-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 27, 2020",Actual,2020-02-27,March 2020,2020-03-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19,"Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","Active, not recruiting",NA,Phase 2/Phase 3,300,Anticipated,China Academy of Chinese Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:23:46Z,2020-04-01T09:23:46Z,Drug|Drug|Other|Other,YinHu QingWen Decoction|YinHu QingWen Decoction(low dose)|Chinese medicine treatment|standard western medicine treatment,"YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.",4,||,Jingzhou Hospital of Traditional Chinese Medicine|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University|Xiangyang Hospital of Traditional Chinese Medicine,Jingzhou|Wuhan|Xiangyang,Hubei|Hubei|Hubei,434000|430200|441000,China|China|China,3
NCT04281693,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-20,NA,NA,2020-02-21,2020-02-21,2020-02-24,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-24,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,A New Screening Strategy for 2019 Novel Coronavirus Infection,Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection,Not yet recruiting,NA,N/A,230,Anticipated,Affiliated Hospital to Academy of Military Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:23:25Z,2020-04-01T09:23:25Z,Diagnostic Test|Diagnostic Test,Standard screening strategy|New screening strategy,The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.,2,,the Fifth Medical Center of Chinese PLA General Hospital,Beijing,Beijing,100071,China,1
NCT04280588,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-20,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Fingolimod in COVID-19,Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,First Affiliated Hospital of Fujian Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-01T09:23:33Z,2020-04-01T09:23:33Z,Drug,Fingolimod 0.5 mg,"Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days",1,Recruiting,Wan-Jin Chen,Fuzhou,,,China,1
NCT04280705,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-20,NA,NA,2020-03-26,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,"February 21, 2020",Actual,2020-02-21,"March 20, 2020",2020-03-20,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2023",Anticipated,2023-04-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,440,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:22:15Z,2020-04-03T09:22:15Z,Other|Drug,Placebo|Remdesivir,"The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients.|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.",2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"University of Alabama at Birmingham School of Medicine - Infectious Disease|University of California San Diego Health - Jacobs Medical Center|University of California Los Angeles Medical Center - Westwood Clinic|University of California Irvine Medical Center - Infectious Disease|VA Palo Alto Health Care System - Infectious Diseases|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases|University of California Davis Medical Center - Internal Medicine - Infectious Disease|Naval Medical Center San Diego - Infectious Disease Clinic|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine|Denver Health Division of Hospital Medicine - Main Campus|Emory Vaccine Center - The Hope Clinic|Northwestern Hospital - Infectious Disease|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore|Johns Hopkins Hospital - Medicine - Infectious Diseases|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section|Walter Reed Army Institute of Research - Clinical Trials Center|Massachusetts General Hospital - Infectious Diseases|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine|Saint Louis University - Center for Vaccine Development|University of Nebraska Medical Center - Infectious Diseases|Montefiore Medical Center - Infectious Diseases|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology|University of Rochester Medical Center - Vaccine Research Unit|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit|Hospital of the University of Pennsylvania - Infectious Diseases|Vanderbilt University Medical Center - Infectious Diseases|Brooke Army Medical Center|University of Texas Medical Branch - Division of Infectious Disease|Baylor College of Medicine - Molecular Virology and Microbiology|University of Texas Health Science Center at San Antonio - Infectious Diseases|Naval Medical Center Portsmouth - Infectious Disease Division|EvergreenHealth Infectious Disease Service|The University of Washington - Virology Research Clinic|Providence Sacred Heart Medical Center|Madigan Army Medical Center - Infectious Disease Clinic|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center|Seoul National University Bundang Hospital - Division of Infectious Diseases|Seoul National University Hospital|National Centre for Infectious Diseases (NCID)",Birmingham|La Jolla|Los Angeles|Orange|Palo Alto|Palo Alto|Sacramento|San Diego|San Francisco|Denver|Decatur|Chicago|Chicago|Annapolis|Baltimore|Bethesda|Silver Spring|Boston|Minneapolis|Saint Louis|Omaha|Bronx|New York|Rochester|Durham|Philadelphia|Nashville|Fort Sam Houston|Galveston|Houston|San Antonio|Portsmouth|Kirkland|Seattle|Spokane|Tacoma|Tokyo|Bundang-gu Seongnam-si|Seoul|Singapore,Alabama|California|California|California|California|California|California|California|California|Colorado|Georgia|Illinois|Illinois|Maryland|Maryland|Maryland|Maryland|Massachusetts|Minnesota|Missouri|Nebraska|New York|New York|New York|North Carolina|Pennsylvania|Tennessee|Texas|Texas|Texas|Texas|Virginia|Washington|Washington|Washington|Washington||Gyeonggi-do|Jongno-gu|,35233|29037|90095|92868-3298|94304-1207|94304-1503|95817-1460|92314|94110-2859|80204|30030-1705|60611-2908|60612|21401-1527|21287-0005|20892-1504|20910-7500|02114-2621|55455-0341|63104-1015|68198-5400|10467-2401|10016-6402|14642|27704|19104-4238|37232-0011|78234|77555-0435|77030-3411|78229-3901|23708|98034|98104-2433|99204|98431|162-8655|13620|03080|308442,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Japan|Korea, Republic of|Korea, Republic of|Singapore",40
NCT04287686,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-21,NA,NA,2020-03-15,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,February 2020,Anticipated,2020-02-29,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,"A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19",Withdrawn,NA,N/A,0,Actual,The First Affiliated Hospital of Guangzhou Medical University,,2,NA,Without CDE Approval,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:38Z,2020-04-01T09:22:38Z,Drug,Recombinant human angiotensin-converting enzyme 2 (rhACE2),"In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.",1,,GCP Office of The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,510120,China,1
NCT04283461,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-21,NA,NA,2020-03-26,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"March 3, 2020",Actual,2020-03-03,"February 20, 2020",2020-02-20,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection,"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",Recruiting,NA,Phase 1,45,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:22:10Z,2020-04-03T09:22:10Z,Biological,mRNA-1273,"Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.",1,Recruiting|Not yet recruiting|Recruiting,Emory Vaccine Center - The Hope Clinic|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases,Decatur|Bethesda|Seattle,Georgia|Maryland|Washington,30030-1705|20892|98101-1466,United States|United States|United States,3
NCT04283838,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Healthcare Workers in Coronavirus Disease 2019,The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,1,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:10Z,2020-04-01T09:23:10Z,Behavioral,Humanistic Care,Psychological and physical rehabilitation based humanistic care regimen,1,NA,NA,NA,NA,NA,NA,NA
NCT04283825,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-22,NA,NA,2020-03-14,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"May 15, 2020",Anticipated,2020-05-15,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Humanistic Care in Patients With Coronavirus Disease 2019,The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With Coronavirus Disease 2019,Withdrawn,NA,N/A,0,Actual,Second Affiliated Hospital of Xi'an Jiaotong University,,2,NA,We cannot enroll enough participants.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:10Z,2020-04-01T09:23:10Z,Behavioral,Psychological and physical rehabilitation based humanistic care,"This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.",1,NA,NA,NA,NA,NA,NA,NA
NCT04293692,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-24,NA,NA,2020-03-15,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"February 24, 2020",Actual,2020-02-24,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus,Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus,Withdrawn,NA,N/A,0,Actual,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,"Patients were transferred to designated hospitals for treatment as needed, the clinical trials
    cannot be conducted.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:55Z,2020-04-01T09:21:55Z,Biological|Other,UC-MSCs|Placebo,"0.5*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7",2,,Puren Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,Hubei,430081,China,1
NCT04288102,"ClinicalTrials.gov processed this data on April 01, 2020",2020-02-24,NA,NA,2020-03-19,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19),"Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19)",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:22:50Z,2020-04-02T09:22:50Z,Biological|Biological,MSCs|Saline containing 1% Human serum albuminï¼ˆsolution of MSCï¼‰,"3 times of MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.|3 times of placeboï¼ˆintravenously at Day 0, Day 3, Day 6ï¼‰",2,Recruiting|Recruiting,Maternal and Child Hospital of Hubei Province|Wuhan Huoshenshan Hospital,Wuhan|Wuhan,Hubei|Hubei,430000|430000,China|China,2
NCT04303299,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-24,NA,NA,2020-03-23,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 15, 2020",Anticipated,2020-03-15,March 2020,2020-03-31,"November 30, 2020",Anticipated,2020-11-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,THDMS-COVID19,,"Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19 : A Randomized Control Trial","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID19",Not yet recruiting,NA,Phase 3,80,Anticipated,Rajavithi Hospital,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:21:23Z,2020-04-03T09:21:23Z,Drug,Oral,Anti virus treatment,1,,Assistant Professor Subsai Kongsaengdao,Bangkok,,10400,Thailand,1
NCT04286503,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-25,NA,NA,2020-02-25,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-27,Actual,"February 23, 2020",Anticipated,2020-02-23,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,The Clinical Study of Carrimycin on Treatment Patients With COVID-19,"The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study",Not yet recruiting,NA,Phase 4,520,Anticipated,Beijing YouAn Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:50Z,2020-04-01T09:22:50Z,Drug|Drug|Drug,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,3,NA,NA,NA,NA,NA,NA,NA
NCT04302519,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-27,NA,NA,2020-03-09,2020-03-09,2020-03-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-09,2020-03-10,Actual,"March 5, 2020",Anticipated,2020-03-05,February 2020,2020-02-29,"July 30, 2021",Anticipated,2021-07-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Not yet recruiting,NA,Early Phase 1,24,Anticipated,"CAR-T (Shanghai) Biotechnology Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:50Z,2020-04-01T09:20:50Z,Biological,Dental pulp mesenchymal stem cells,"On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.",1,NA,NA,NA,NA,NA,NA,NA
NCT04291053,"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-27,NA,NA,2020-03-14,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"September 1, 2020",Anticipated,2020-09-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19,"The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study",Not yet recruiting,NA,Phase 2/Phase 3,550,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:15Z,2020-04-01T09:22:15Z,Drug,Huaier Granule,standard treatment + Huaier Granule 20g po tid for 2weeks,1,NA,NA,NA,NA,NA,NA,NA
NCT04291729,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-27,NA,NA,2020-03-20,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-20,2020-03-24,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of Novel Coronavirus Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of Novel Coronavirusï¼ˆ2019-nCoVï¼‰ Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:21:48Z,2020-04-03T09:21:48Z,Drug,Ganovo+ritonavir+/-Interferon nebulization,"Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50Î¼g / time for adults, twice a day up to 14 days.",1,,The Ninth Hospital of Nanchang,Nanchang,Jiangxi,330000,China,1
NCT04290871,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-27,NA,NA,2020-03-22,2020-02-27,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.,Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.,Withdrawn,NA,Phase 2,0,Actual,Xijing Hospital,,2,NA,A new coordinating center has been defined (Massachusetts General Hospital),FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:21:51Z,2020-04-03T09:21:51Z,Drug,Nitric Oxide Gas,"Inspired NO will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment. After that, NO levels will be decreased to 40 ppm until severe hypoxia resolves. Weaning from NO will start when patients improves the level of oxygenation to a PaO2/FiO2 > 300 mmHg or SpO2 > 93% for more than 24 hours consecutively. Physician will follow their own institutional weaning protocols. In the absence of institutional protocols, NO will be reduced every 4 hours in step-wise fashion starting from 40 ppm to 20, 10, 5, 3, 2 and 1 ppm.",1,NA,NA,NA,NA,NA,NA,NA
NCT04290858,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-27,NA,NA,2020-03-22,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"February 1, 2022",Anticipated,2022-02-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial,Withdrawn,NA,Phase 2,0,Actual,Xijing Hospital,,2,NA,New coordinating center has been defined (Massachusetts General Hospital),FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:21:51Z,2020-04-03T09:21:51Z,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.",1,NA,NA,NA,NA,NA,NA,NA
NCT04299152,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-28,NA,NA,2020-03-26,2020-03-05,2020-03-06,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"April 10, 2020",Anticipated,2020-04-10,March 2020,2020-03-31,"November 10, 2020",Anticipated,2020-11-10,"October 9, 2020",Anticipated,2020-10-09,NA,Interventional,NA,,Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2,Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Not yet recruiting,NA,Phase 2,20,Anticipated,Tianhe Stem Cell Biotechnologies Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:21:30Z,2020-04-03T09:21:30Z,Combination Product,Stem Cell Educator-Treated Mononuclear Cells Apheresis,"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the ""educated"" autologous immune cells to the patient's circulation.",1,NA,NA,NA,NA,NA,NA,NA
NCT04292899,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-28,NA,NA,2020-04-01,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Recruiting,NA,Phase 3,400,Anticipated,Gilead Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:21:43Z,2020-04-03T09:21:43Z,Drug|Drug,Remdesivir|Standard of Care,Administered as an intravenous infusion|Standard of care therapy per local written policies or guidelines,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave.|Kaiser Permanente Los Angeles Medical Center|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave.|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue|Hoag Memorial Hospital Presbyterian|Kaiser Permanente Oakland Medical Center|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd|Providence St. Johns Medical Center|Sutter Santa Rosa Regional Hospital|Stanford Hospital|Yale-New Haven Hospital|John H. Stroger Jr. Hospital of Cook County|Rush University Medical Center|University of Chicago|Tufts Medical Center|Brigham & Women's Hospital and Harvard Medical School|Beth Israel Deaconess Medical Center|Hennepin County Medical Center|Mayo Clinic|Darmouth-Hitchhock Medical Center|Hackensack University Medical Center|Robert Wood Johnson University Hospital Somerset|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue|Jacobi Medical Center|James J. Peters Veterans Administration Medical Center|Jamaica Hospital Medical Center|Danbury Hospital|North Shore University Hospital|Icahn School of Medicine at Mount Sinai, 350 East 17th Street|Icahn School of Medicine at Mount Sinai, 440 West 114th St.|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue|Icahn School of Medicine at Mount Sinai|Columbia University Irving Medical Center|Columbia University Medical Center-New York Presbyterian Hospital|New York Presbyterian Hospital/Weill Cornell Medical Center|University Hospitals Cleveland Medical Center|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave|Providence Portland Medical Center|Providence St. Vincent Medical Center|Kaiser Sunnyside Medical Center|Hospital of the University of Pennsylvania|The Miriam Hospital|UT Southwestern Medical Center Amelia Court, HIV Research Clinic|Baylor University Medical Center|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd.|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd|Baylor University Medical Center, 1400 8th Ave|Houston Methodist Hospital|Baylor University Medical Center, 2401 S. 31st St.|Inova Fairfax Medical Campus|VCU Health Medical Center|Providence Regional Medical Center Everett|Virginia Mason Medical Center|Swedish Center for Comprehensive Care|MultiCare Deaconess Hospital|MultiCare Tacoma General Hospital|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2|Prince of Wales Hospital|Princess Margaret Hospital|Queen Mary Hospital|ASST degli Spedali Civili di Brescia|ASST di Cremona - Azienda Socio Sanitaria Territor|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova|Azienda Ospedaliero Universitaria di Parma|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|Hospital Clinic de Barcelona|Hospital Universitario La Paz|Hopitaux Universitaires de GenÃ¨ve|Ospedale Regionale di Locarno La CaritÃ |UniversitÃ¤tsspital ZÃ¼rich|Kaohsiung Veterans General Hospital|China Medical University Hospital|National Taiwan University Hospital|King's College Hospital NHS Trust|Pennine Acute Hospitals NHS Trust",Anaheim|Downey|Fontana|Harbor City|Los Angeles|Los Angeles|Los Angeles|Los Angeles|Moreno Valley|Newport Beach|Oakland|Ontario|Panorama City|San Diego|San Diego|San Francisco|Santa Monica|Santa Rosa|Stanford|New Haven|Chicago|Chicago|Chicago|Boston|Boston|Boston|Minneapolis|Rochester|Lebanon|Hackensack|Hillsborough|New Brunswick|Newark|Bronx|Bronx|Jamaica|Lagrangeville|Manhasset|New York|New York|New York|New York|New York|New York|New York|Cleveland|Hillsboro|Portland|Portland|Portland|Philadelphia|Providence|Dallas|Dallas|Dallas|Dallas|Fort Worth|Houston|Temple|Falls Church|Richmond|Everett|Seattle|Seattle|Spokane|Tacoma|Munich|Hong Kong|Hong Kong|Hong Kong|Brescia|Cremona|Padova PD|Parma|Pavia|Daegu|Seoul|Seoul|Singapore|Singapore|Singapore|Barcelona|Madrid|GenÃ¨ve 14|Lugano|ZÃ¼rich|Kaohsiung|Taichung|Taipei City|London|Manchester,California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|Connecticut|Illinois|Illinois|Illinois|Massachusetts|Massachusetts|Massachusetts|Minnesota|Minnesota|New Hampshire|New Jersey|New Jersey|New Jersey|New Jersey|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|Ohio|Oregon|Oregon|Oregon|Oregon|Pennsylvania|Rhode Island|Texas|Texas|Texas|Texas|Texas|Texas|Texas|Virginia|Virginia|Washington|Washington|Washington|Washington|Washington|||||||||||||||||||||||||,92806|90241|92335|90710|90027|90034|91365|92505|92555|92658|94611|91761|91402|18038|92120-2507|94115|90404|95403|94305|06510|60612|60612|60637|02111|02115|02215|55415|55905|03756|07601|08844|08901|07112|10461|10468|11418|12540|11030|10003|10025|10029|10029|10032|10032|10065|44106|97124|97213|97225|97227|19104|02906|75235|75246|75390|75390|76104|77030|76508|22042|23298|98201|98101|98104|99204|98405|81675||||25123|26100|35121|43126|27100|41944|02053|04564|119228|169856|308442|8036|28046|1211|CH- 6900|8091|81362|40447|10002|SE5 9RS|M8 5RB,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Germany|Hong Kong|Hong Kong|Hong Kong|Italy|Italy|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Singapore|Singapore|Singapore|Spain|Spain|Switzerland|Switzerland|Switzerland|Taiwan|Taiwan|Taiwan|United Kingdom|United Kingdom",91
NCT04292730,"ClinicalTrials.gov processed this data on April 02, 2020",2020-02-28,NA,NA,2020-04-01,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"March 15, 2020",Actual,2020-03-15,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Recruiting,NA,Phase 3,600,Anticipated,Gilead Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:21:44Z,2020-04-03T09:21:44Z,Drug|Drug,Standard of Care|Remdesivir,Standard of care therapy per local written policies or guidelines|Administered as an intravenous infusion,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Queen Mary Hospital|ASST degli Spedali Civili di Brescia|Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave.|Kaiser Permanente Los Angeles Medical Center|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave.|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue|Hoag Memorial Hospital Presbyterian|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd|Providence St. Johns Medical Center|Sutter Santa Rosa Regional Hospital|Stanford Hospital|Yale University|Cook County General Hospital|University of Chicago|University of Iowa Hospitals & Clinics|Tufts Medical Center|Brigham & Women's Hospital and Harvard Medical School|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center|Hennepin Healthcare|Mayo Clinic Rochester|Darmouth-Hitchhock Medical Center|Hackensack Medical Center|RBWJ University Hospital/Newark Beth Israel Medical Center|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue|Jacobi Medical Center|James J. Peters Veterans Administration Medical Center|Jamaica Hospital Medical Center|Danbury Hospital|North Shore University Hospital|Icahn School of Medicine at Mount Sinai, 350 East 17th Street|Icahn School of Medicine at Mount Sinai, 440 West 114th St.|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue|Icahn School of Medicine at Mount Sinai|Columbia University Irving Medical Center|Weill Cornell Medical College/NYU Presbyterian Hospital|University Hospitals Cleveland Medical Center|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave|Providence Portland Medical Center|Providence St. Vincent Medical Center|Kaiser Sunnyside Medical Center|Hospital of the University of Pennsylvania|Temple University Hospital|The Miriam Hospital|UTSW Medical Center|Baylor University Medical Center|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd.|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd|Baylor University Medical Center, 1400 8th Ave|Houston Methodist Hospital|Baylor University Medical Center, 2401 S. 31st St.|Inova Fairfax Hospital|VCU Health Medical Center|Providence Medical Research Center|Virginia Mason Medical Center|Swedish Center for Comprehensive Care|MultiCare Deaconess Hospital|MultiCare Tacoma General Hospital|The First Affiliated Hospital of Guangzhou Medical University|University Clinic DÃ¼sseldorf|Universitatsklinikum Hamburg-Eppendorf|UniversitÃ¤tsklinikum Schleswig-Holstein Campus Kiel|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2|Prince of Wales Hospital|Princess Margaret Hospital|ASST di Cremona - Azienda Socio Sanitaria Territor|ASST Fatebenefratelli Sacco|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova|Azienda Ospedaliero Universitaria di Parma|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo|Kyungpook National University Hospital|Seoul Medical Center|National Medical Center|National University Hospital|Singapore General Hospital|National Centre for Infectious Diseases, Tan Tock Seng Hospital|Hospital Clinic de Barcelona|Hospital Universitario Cruces|Hospital Universitario La Paz|Hopitaux Universitaires de GenÃ¨ve|Ospedale Regionale di Locarno La CaritÃ |UniversitÃ¤tsspital ZÃ¼rich|Kaohsiung Veterans General Hospital|China Medical University Hospital|National Taiwan University Hospital|King's College Hospital NHS Trust|Pennine Acute Hospitals NHS Trust",Hong Kong|Brescia|Anaheim|Downey|Fontana|Harbor City|Los Angeles|Los Angeles|Los Angeles|Los Angeles|Moreno Valley|Newport Beach|Ontario|Panorama City|San Diego|San Diego|San Francisco|Santa Monica|Santa Rosa|Stanford|New Haven|Chicago|Chicago|Iowa City|Boston|Boston|Boston|Minneapolis|Rochester|Lebanon|Hackensack|Hillsborough|New Brunswick|Newark|Bronx|Bronx|Jamaica|Lagrangeville|Manhasset|New York|New York|New York|New York|New York|New York|Cleveland|Hillsboro|Portland|Portland|Portland|Philadelphia|Philadelphia|Providence|Dallas|Dallas|Dallas|Dallas|Fort Worth|Houston|Temple|Falls Church|Richmond|Everett|Seattle|Seattle|Spokane|Tacoma|Guangzhou|DÃ¼sseldorf|Hamburg|Kiel|Munich|Hong Kong|Hong Kong|Cremona|Milano|Padova PD|Parma|Pavia|Daegu|Seoul|Seoul|Singapore|Singapore|Singapore|Barcelona|Bizkaia|Madrid|GenÃ¨ve 14|Lugano|ZÃ¼rich|Kaohsiung|Taichung|Taipei City|London|Manchester,||California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|California|Connecticut|Illinois|Illinois|Iowa|Massachusetts|Massachusetts|Massachusetts|Minnesota|Minnesota|New Hampshire|New Jersey|New Jersey|New Jersey|New Jersey|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|Ohio|Oregon|Oregon|Oregon|Oregon|Pennsylvania|Pennsylvania|Rhode Island|Texas|Texas|Texas|Texas|Texas|Texas|Texas|Virginia|Virginia|Washington|Washington|Washington|Washington|Washington|||||||||||||||||||||||||||||,|25123|92806|90241|92335|90710|90027|90034|91365|92505|92555|92658|91761|91402|18038|92120-2507|94115|90404|95403|94305|06510|60612|60637|52242|02111|02115|02215|55415|55905|03756|07601|08844|08901|07112|10461|10468|11418|12540|11303|10003|10025|10029|10029|10032|10065|44106|97124|97213|97225|97227|19104|19140|02906|75235|75246|75390|75390|76104|77030|76508|22042|23298|98201|98101|98104|99204|98405||40225|20246|24105|81675|||26100|20157|35121|43126|27100|41944|02053|04564|119228|169856|308442|8036|48903|28046|1211|CH- 6900|8091|81362|40447|10002|SE5 9RS|M8 5RB,"Hong Kong|Italy|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|China|Germany|Germany|Germany|Germany|Hong Kong|Hong Kong|Italy|Italy|Italy|Italy|Italy|Korea, Republic of|Korea, Republic of|Korea, Republic of|Singapore|Singapore|Singapore|Spain|Spain|Spain|Switzerland|Switzerland|Switzerland|Taiwan|Taiwan|Taiwan|United Kingdom|United Kingdom",96
NCT04296643,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-05,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"January 1, 2021",Anticipated,2021-01-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Not yet recruiting,NA,N/A,576,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:31Z,2020-04-01T09:21:31Z,Device|Device,Medical Mask|N95 respirator,Medical Mask (known also as Surgical Mask)|N95 respirator,2,NA,NA,NA,NA,NA,NA,NA
NCT04295551,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-04,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"March 14, 2020",Anticipated,2020-03-14,March 2020,2020-03-31,"April 14, 2021",Anticipated,2021-04-14,"July 14, 2020",Anticipated,2020-07-14,NA,Interventional,NA,,Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Not yet recruiting,NA,N/A,80,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:39Z,2020-04-01T09:21:39Z,Drug|Drug,Lopinavir / ritonavir tablets combined with Xiyanping injection|Lopinavir/ritonavir treatment,"Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
NCT04308317,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:05Z,2020-04-01T09:20:05Z,Drug,Tetrandrine,Tetrandrine 60mg QD for 1week,1,,Tetrandrine Tablets,Jinhua,Zhejiang,321000,China,1
NCT04299724,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:21:09Z,2020-04-01T09:21:09Z,Biological,Pathogen-specific aAPC,The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.,1,Recruiting,Shenzhen Geno-immune Medical Institute,Shenzhen,Guangdong,518000,China,1
NCT04304053,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-05,NA,NA,2020-03-22,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"June 15, 2020",Anticipated,2020-06-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,HCQ4COV19,,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Recruiting,NA,Phase 3,3040,Anticipated,Fundacio Lluita Contra la SIDA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:21:20Z,2020-04-03T09:21:20Z,Drug|Other,Antiviral treatment and prophylaxis|Standard Public Health measures,"darunavir 800 mg / cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4, 5, 6 and 7.
Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4.|Isolation of patient and contact tracing as per national guidelines.",2,Recruiting|Recruiting|Recruiting,CAP II Sant FÃ¨lix|GerÃ¨ncia Territorial Catalunya Central|Centre de Salut Isabel Roig-Casernes de Sant Andreu,Sabadell|Sant FruitÃ³s De Bages|Barcelona,Barcelona|Barcelona|,08204|08272|08030,Spain|Spain|Spain,3
NCT04303507,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-06,NA,NA,2020-03-25,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COPCOV,,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Not yet recruiting,NA,N/A,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2020-04-03T09:21:22Z,2020-04-03T09:21:22Z,Drug|Drug,Chloroquine or Hydroxychloroquine|Placebo,A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months|Placebo,2,NA,NA,NA,NA,NA,NA,NA
NCT04306055,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-08,NA,NA,2020-03-10,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-10,2020-03-12,Actual,"March 12, 2020",Anticipated,2020-03-12,March 2020,2020-03-31,"April 9, 2020",Anticipated,2020-04-09,"March 19, 2020",Anticipated,2020-03-19,NA,Interventional,NA,,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Not yet recruiting,NA,N/A,1500,Anticipated,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:22Z,2020-04-01T09:20:22Z,Other|Other,Questionnaire with precaution information|Experimental: Questionnaire without precaution information,Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.|Ever blood donors in this group would receive a questionnaire which dose not include the information above.,2,NA,NA,NA,NA,NA,NA,NA
NCT04323332,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-08,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,Traditional Chinese Medicine for Severe COVID-19,A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19,Not yet recruiting,NA,Phase 3,50,Anticipated,Xiyuan Hospital of China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-03T09:17:23Z,2020-04-03T09:17:23Z,Drug,Traditional Chinese Medicine Prescription,Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.,1,,Hao Li,Beijing,Beijing,100091,China,1
NCT04310228,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-09,NA,NA,2020-03-14,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"March 8, 2020",Actual,2020-03-08,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,N/A,150,Anticipated,Peking University First Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:19:49Z,2020-04-01T09:19:49Z,Drug|Drug|Drug,Favipiravir Combined With Tocilizumab|Favipiravir|Tocilizumab,"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications â‰¥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications â‰¥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.",3,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Anhui Medical University Affiliated First Hospital|Guiqiang Wang|Peking University First Hospital|Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology|Ezhou Central Hospital|Huoshenshan Hospital of Wuhan|Jinyintan Hospital of Wuhan|Tongji Hospital of Huazhong University of Science and Technology|West Hospital Union Hospital Huazhong University of Science and Technology|Wuhan Pulmonary Hospital|Zhongnan Hospital of Wuhan University,Hefei|Beijing|Beijing|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan|Wuhan,Anhui|Beijing|Beijing|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei|Hubei,230022|100034|100034|430000|430000|430000|430000|430000|430000|430000|430000,China|China|China|China|China|China|China|China|China|China|China,11
NCT04304690,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-09,NA,NA,2020-03-17,2020-03-09,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"October 16, 2020",Anticipated,2020-10-16,"July 16, 2020",Anticipated,2020-07-16,NA,Interventional,SEROCOV,,"Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Sars-CoV2 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic",Recruiting,NA,N/A,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:32Z,2020-04-01T09:20:32Z,Other,blood sample,2 blood samples at T0 and 3 months,1,Recruiting,Hopital PitiÃ© SalpetriÃ¨re,Paris,,75013,France,1
NCT04305457,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-09,NA,NA,2020-03-21,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-21,2020-03-24,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,Recruiting,NA,Phase 2,240,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:21:14Z,2020-04-03T09:21:14Z,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.",1,Recruiting,Massachusetts General Hospital,Boston,Massachusetts,02114-2621,United States,1
NCT04305106,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-09,NA,NA,2020-03-24,2020-03-09,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,BEST-RCT,,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial,Recruiting,NA,N/A,140,Anticipated,Qilu Hospital of Shandong University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:21:15Z,2020-04-03T09:21:15Z,Drug,Bevacizumab,"Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip",1,Recruiting,Qilu Hospital of Shandong University,Jinan,Shandong,250012,China,1
NCT04307693,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-10,NA,NA,2020-03-12,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-12,2020-03-13,Actual,"March 11, 2020",Actual,2020-03-11,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,Asan Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:10Z,2020-04-01T09:20:10Z,Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate,Lopinavir / Ritonavir tablet|Hydroxychloroquine sulfate tablet,2,Recruiting,"Asan Medical Center, University of Ulsan College of Medicine",Seoul,,138-736,"Korea, Republic of",1
NCT04306393,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-10,NA,NA,2020-03-21,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-21,2020-03-24,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"March 21, 2022",Anticipated,2022-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,Recruiting,NA,Phase 2,200,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:21:10Z,2020-04-03T09:21:10Z,Drug,Nitric Oxide Gas,"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.
Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.",1,Recruiting,Massachusetts General Hospital,Boston,Massachusetts,02114,United States,1
NCT04308668,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-11,NA,NA,2020-03-25,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"May 12, 2020",Anticipated,2020-05-12,"April 21, 2020",Anticipated,2020-04-21,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis and Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 3,3000,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:21:05Z,2020-04-03T09:21:05Z,Drug|Other,Hydroxychloroquine|Placebo,"200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days",2,Recruiting|Recruiting|Recruiting,"Nationwide Enrollment via Internet, please email: covid19@umn.edu|University of Minnesota|Internet",Minneapolis|Minneapolis|New York,Minnesota|Minnesota|New York,55455|55455|10001,United States|United States|United States,3
NCT04316377,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-13,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 3, 2025",Anticipated,2025-03-03,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 4,202,Anticipated,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:19:03Z,2020-04-01T09:19:03Z,Drug,Hydroxychloroquine Sulfate,400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days,1,NA,NA,NA,NA,NA,NA,NA
NCT04312009,"ClinicalTrials.gov processed this data on April 01, 2020",2020-03-13,NA,NA,2020-03-19,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Not yet recruiting,NA,Phase 2,200,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-02T09:21:48Z,2020-04-02T09:21:48Z,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,||,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
NCT04311177,"ClinicalTrials.gov processed this data on April 01, 2020",2020-03-13,NA,NA,2020-03-19,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Not yet recruiting,NA,Phase 2,516,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-02T09:21:52Z,2020-04-02T09:21:52Z,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,||,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
NCT04315948,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-13,NA,NA,2020-03-23,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,3100,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:20:44Z,2020-04-03T09:20:44Z,Drug|Drug|Drug|Drug|Other,Remdesivir|Lopinavir/ritonavir|Interferon Beta-1A|Hydroxychloroquine|Standard of care,"The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.|The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the ""a"" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).|IFN-ÃŸ-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 Âµg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).|Standard of care.",5,Recruiting|Recruiting|Recruiting,CHRU Lille|CHU Nantes|APHP - Bichat Claude Bernard,Lille|Nantes|Paris,||,59000|44000|75018,France|France|France,3
NCT04316728,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-14,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19,Not yet recruiting,NA,N/A,200,Anticipated,"Centro Studi Internazionali, Italy",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months,Still under development,NA,Yes,Still under development,2020-04-01T09:19:01Z,2020-04-01T09:19:01Z,Device,VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test,"VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma",1,,"UnitÃ ' Complesse di cure primarie (UCCP), ASP Catanzaro",Catanzaro,,88100,Italy,1
NCT04315480,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-14,NA,NA,2020-03-18,2020-03-18,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-19,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Tocilizumab for SARS-CoV2 Severe Pneumonitis,Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 Infection With Severe Multifocal Interstitial Pneumonia,Not yet recruiting,NA,Phase 2,30,Anticipated,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-01T09:19:10Z,2020-04-01T09:19:10Z,Drug,Tocilizumab,single intravenous administration 8mg/Kg,1,,UniversitÃ  Politecnica delle Marche,Ancona,AN,60020,Italy,1
NCT04311697,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-14,NA,NA,2020-03-24,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Not yet recruiting,NA,Phase 2,120,Anticipated,"NeuroRx, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-03T09:21:00Z,2020-04-03T09:21:00Z,Drug|Drug,Aviptadil by intravenous infusion + maximal intensive care|Normal Saline Infusion + Maximal intensive care,Aviptadil by intravenous infusion + maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.|Maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.,2,|,Research Center|Rambam Health Care Campus,New York|Haifa,New York|,10016|3109601,United States|Israel,2
NCT04313322,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:19:25Z,2020-04-01T09:19:25Z,Biological,WJ-MSCs,"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.",1,Recruiting,Stem Cells Arabia,Amman,,11953,Jordan,1
NCT04312243,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-15,NA,NA,2020-03-16,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-18,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"March 20, 2022",Anticipated,2022-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NOpreventCOVID,,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,Not yet recruiting,NA,Phase 2,460,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-01T09:19:33Z,2020-04-01T09:19:33Z,Drug,Inhaled nitric oxide gas,"Observational group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.",1,NA,NA,NA,NA,NA,NA,NA
NCT04310865,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"June 30, 2021",Anticipated,2021-06-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,"An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",Not yet recruiting,NA,Phase 2/Phase 3,116,Anticipated,China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:19:45Z,2020-04-01T09:19:45Z,Drug|Drug|Other,Yinhu Qingwen Granula|Yin Hu Qing Wen Granula(low does)|standard medical treatment,"Yinhu Qingwen Granula is a kind of herbal granula made from ""Yinhu Qingwen Decoction"", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.",3,|||,Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University,Wuhan|Wuhan|Wuhan|Wuhan,Hubei|Hubei|Hubei|Hubei,430071|430071|430071|430200,China|China|China|China,4
NCT04315298,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-15,NA,NA,2020-03-26,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"March 16, 2021",Anticipated,2021-03-16,"March 16, 2021",Anticipated,2021-03-16,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,Regeneron Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://errs.regeneron.com/external,Yes,All IPD that underlie publicly available results will be considered for sharing,2020-04-03T09:20:47Z,2020-04-03T09:20:47Z,Drug|Drug,Sarilumab|Placebo,Single intravenous (IV) dose of sarilumab|Single intravenous (IV) dose of placebo to match sarilumab administration,2,Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting,Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site 1|Regeneron Study Site 2|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Facility 2|Regeneron Study Site 1|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site 1|Regeneron Study Site 2|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site|Regeneron Study Site,Los Angeles|Palo Alto|Sacramento|Santa Monica|Aurora|Denver|New Haven|Washington|Coral Gables|Gainesville|Orlando|Atlanta|Decatur|Marietta|Chicago|Baltimore|Boston|Boston|Boston|Boston|Ann Arbor|Detroit|Rochester|Edison|Hackensack|Livingston|Morristown|Neptune|Newark|Teaneck|Bronx|Bronx|Bronx|Bronx|Brooklyn|Elmhurst|Manhasset|Manhasset|New York|New York|New York|New York|New York|New York|New York|New York|Stony Brook|Valhalla|Portland|Portland|Philadelphia|Dallas|Dallas|Murray|Falls Church|Everett|Renton,California|California|California|California|Colorado|Colorado|Connecticut|District of Columbia|Florida|Florida|Florida|Georgia|Georgia|Georgia|Illinois|Maryland|Massachusetts|Massachusetts|Massachusetts|Massachusetts|Michigan|Michigan|Minnesota|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|New York|Oregon|Oregon|Pennsylvania|Texas|Texas|Utah|Virginia|Washington|Washington,90095|94304|95817|90404|80045|80206|06520|20010|33146|32610|32803|30322|30033|30060|60611|21205|02111|02114|02115|02215|48109|48236|55905|08820|07601|07039|07960|07753|07112|07666|10451|10461|10461|10467|11219|11373|11030|11030|10003|10016|10025|10025|10029|10032|10037|10065|11794|10595|97213|97239|19140|75246|75390|84107|22042|98201|98055,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,57
NCT04313127,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-15,NA,NA,2020-03-29,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-29,2020-03-31,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,APICTH,,A Phase I Clinical Trial in 18-60 Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Active, not recruiting",NA,Phase 1,108,Anticipated,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:20:54Z,2020-04-03T09:20:54Z,Biological,Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Intramuscular other name:Ad5-nCoV,1,,Hubei Provincial Center for Disease Control and Prevention,Wuhan,Hubei,,China,1
NCT04313023,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-16,NA,NA,2020-03-22,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing COVID-19 Infection in Adults Exposed to COVID-19,Not yet recruiting,NA,Phase 2,200,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:20:55Z,2020-04-03T09:20:55Z,Drug|Drug,PUL-042 Inhalation Solution|Placebo,"20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042) PUL-042 Inhalation Solution will be given by nebulization on study days 1, 3, 6, and 10|Sterile normal saline for inhalation",2,NA,NA,NA,NA,NA,NA,NA
NCT04312997,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-16,NA,NA,2020-03-22,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Not yet recruiting,NA,Phase 2,100,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:20:55Z,2020-04-03T09:20:55Z,Drug|Drug,PUL-042 Inhalation Solution|Placebo,"20.3 Âµg Pam2 : 29.8 Âµg ODN/mL (50 Âµg PUL-042) given by nebulization on study days 1, 3 and 6|Sterile normal saline for inhalation",2,,Houston Methodist Hospital,Houston,Texas,77030,United States,1
NCT04315896,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-18,NA,NA,2020-03-18,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"March 22, 2021",Anticipated,2021-03-22,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,HYDRA,,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),Not yet recruiting,NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,As requested by other investigators.,2020-04-01T09:19:06Z,2020-04-01T09:19:06Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,hydroxychloroquine 400mg day for 10 days|Placebo oral tablet,2,NA,NA,NA,NA,NA,NA,NA
NCT04323514,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-18,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"March 13, 2021",Anticipated,2021-03-13,"March 13, 2021",Anticipated,2021-03-13,NA,Interventional,NA,,Use of Ascorbic Acid in Patients With COVID 19,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,NA,N/A,500,Anticipated,University of Palermo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:17:17Z,2020-04-03T09:17:17Z,Dietary Supplement,Vitamin C,10 gr of vitamin C intravenously in addition to conventional therapy.,1,Recruiting,A.R.N.A.S. Civico - Di Cristina - Benfratelli,Palermo,,90127,Italy,1
NCT04321174,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-18,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 30, 2020",Anticipated,2020-03-30,March 2020,2020-03-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Not yet recruiting,NA,Phase 3,1220,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,TBA,2020-04-03T09:18:43Z,2020-04-03T09:18:43Z,Drug,Lopinavir/ritonavir,"The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.",1,||,Sunnybrook Hospital|St. Michael's Hospital|Toronto General Hospital,Toronto|Toronto|Toronto,Ontario|Ontario|Ontario,M4N 3M5|M5B 1W8|M5G 2N2,Canada|Canada|Canada,3
NCT04315987,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-18,NA,NA,2020-03-29,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-29,2020-03-31,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,HOPE,,NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Exploratory Clinical Study to Assess the Efficacy of NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Not yet recruiting,NA,Phase 1,66,Anticipated,Azidus Brasil,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-04-03T09:20:43Z,2020-04-03T09:20:43Z,Biological|Biological,NestCellÂ®|NestCellÂ®,"Phase 1 of the study: 6 patients will receive conventional treatment plus 3 times of 1x10^6 cells /kg body weight of NestCellÂ® intravenously on Day1, Day3 and Day7|Phase 2 of the study: After Safety Monitoring Board evaluation, 60 patients will receive conventional treatment plus the dose and posology of NestCellÂ® recommended by Board.",2,,Prevent Senior Private Operadora de SaÃºde LTDA.,SÃ£o Paulo,,04547-100,Brazil,1
NCT04317092,"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"December 19, 2022",Anticipated,2022-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,TOCIVID-19,,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,330,Anticipated,"National Cancer Institute, Naples",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:18:59Z,2020-04-01T09:18:59Z,Drug,Tocilizumab Injection,"Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose), with an interval of 12 hours.",1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia)|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive)|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza)|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O.|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive)|ASST OVEST MILANESE presidi Legnano - Magenta|Azienda Ospedaliero-Universitaria di Modena|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I)|A.O.U. di Modena (Dipartimento Chirurgie Generali e SpecialitÃ  Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II)|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive)|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia)|National Cancer Institute|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva)|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio)|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza)|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione)|Grande Ospedale Metropolitano, Reggio Calabria|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive)|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche)|ASST Sette Laghi (Dipartimento di Medicina Interna)|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze)|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale)|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali)|A.O.U. Integrata di Verona (Dip. Malattie Infettive)|Ospedale Magalini (U.O. Malattie Infettive)",Alessandria|Busto Arsizio|Catania|Catania|Cosenza|Magenta|Modena|Modena|Modena|Modena|Modena|Naples|Naples|Naples|Naples|Pesaro|Pozzuoli|Ravenna|Reggio Calabria|Rimini|Rome|Varese|Varese|Varese|Varese|Verona|Villafranca Di Verona,||||||||||||||||||||||||||,||||||42100|||||80131|80131||||||||||||||,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,27
NCT04318015,"ClinicalTrials.gov processed this data on April 01, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Not yet recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-02T09:20:47Z,2020-04-02T09:20:47Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,All treatment will be administered orally.|All placebo will be administered orally,2,NA,NA,NA,NA,NA,NA,NA
NCT04317040,"ClinicalTrials.gov processed this data on April 01, 2020",2020-03-19,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,May 2020,Anticipated,2020-05-31,March 2020,2020-03-31,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Not yet recruiting,NA,Phase 3,230,Anticipated,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:21:22Z,2020-04-02T09:21:22Z,Drug|Drug,CD24Fc|Placebo,CD24Fc is given on Day 1.|Placebo is given on Day 1.,2,,"Institute of Human Virology, University of Maryland Baltimore",Baltimore,Maryland,21201,United States,1
NCT04323592,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-19,NA,NA,2020-03-25,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"May 30, 2020",Anticipated,2020-05-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,MP-C19,,Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Recruiting,NA,Phase 2/Phase 3,104,Anticipated,University of Trieste,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed,2020-04-03T09:17:14Z,2020-04-03T09:17:14Z,Drug|Other,Methylprednisolone|standard care,"Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description|usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins",2,Recruiting,Marco Confalonieri,Trieste,TS,34149,Italy,1
NCT04323527,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-19,NA,NA,2020-03-27,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-30,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Recruiting,NA,Phase 2,440,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2020-04-03T09:17:16Z,2020-04-03T09:17:16Z,Drug,Chloroquine diphosphate,150mg chloroquine diphosphate tablets.,1,Recruiting,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
NCT04320056,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-19,NA,NA,2020-03-26,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"October 31, 2021",Anticipated,2021-10-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia,Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia),Not yet recruiting,NA,N/A,216,Anticipated,Laval University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No There is not plan to share individual participant data. All data if shared with be de-identified. Data will be stored on a secure server with access only by study personal.,2020-04-03T09:19:25Z,2020-04-03T09:19:25Z,Other|Device,Standard administration of oxygen flow|Automated oxygen administration - FreeO2,"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.
In this group the SpO2 was recorded any time with FreeO2 device - recording mode|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)",2,NA,NA,NA,NA,NA,NA,NA
NCT04324606,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-26,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers",Not yet recruiting,NA,Phase 1/Phase 2,510,Anticipated,University of Oxford,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:16:40Z,2020-04-03T09:16:40Z,Biological|Other,ChAdOx1 nCoV-19|Saline Placebo,5x10^10vp of ChAdOx1 nCoV-19|Saline injection delivered intramuscularly,2,|||,"NIHR WTCRF, University Hospital Southampton NHS Foundation Trust|Imperial College Healthcare NHS Trust|CCVTM, University of Oxford, Churchill Hospital|John Radcliffe Hospital",Southampton|London|Oxford|Oxford,Hampshire|||,SO16 6YD|W2 1NY|OX3 7LE|OX3 9DU,United Kingdom|United Kingdom|United Kingdom|United Kingdom,4
NCT04321928,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-25,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"August 21, 2021",Anticipated,2021-08-21,"April 21, 2021",Anticipated,2021-04-21,NA,Interventional,PROACTIVE-19,,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Not yet recruiting,NA,N/A,7576,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:18:16Z,2020-04-03T09:18:16Z,Behavioral|Behavioral,Personalized health education|General health education,"Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.",2,NA,NA,NA,NA,NA,NA,NA
NCT04320277,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,BARI-COVID,,"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study",Recruiting,NA,Phase 3,60,Anticipated,Hospital of Prato,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:19:18Z,2020-04-03T09:19:18Z,Drug,Baricitinib,Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.,1,Recruiting,Fabrizio Cantini,Prato,Tuscany,59100,Italy,1
NCT04319900,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:19:32Z,2020-04-03T09:19:32Z,Drug|Drug|Drug,favipiravir tablets+chloroquine phosphatetablets tablets|Favipiravir tablets|Placebo,"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).
Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.",3,Recruiting,Beijing Chaoyang hospital,Beijing,Beijing,100020,China,1
NCT04319445,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mindfulness During COVID-19,Mindfulness During COVID-19 - Remote Mindfulness Sessions,Not yet recruiting,NA,N/A,200,Anticipated,Wake Forest University Health Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:19:47Z,2020-04-03T09:19:47Z,Behavioral,Mindfulness session(s),"The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).",1,NA,NA,NA,NA,NA,NA,NA
NCT04318444,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-24,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Not yet recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:20:24Z,2020-04-03T09:20:24Z,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,"Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.",2,,Columbia University Irving Medical Center,New York,New York,10032,United States,1
NCT04320953,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-21,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 16, 2020",Actual,2020-03-16,March 2020,2020-03-31,"March 16, 2020",Actual,2020-03-16,"March 16, 2020",Actual,2020-03-16,NA,Interventional,NA,,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,N/A,1,Actual,Changhai Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:18:50Z,2020-04-03T09:18:50Z,Device,Non-contact MCE system,"After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.",1,,Changhai Hospital,Shanghai,,200433,China,1
NCT04325867,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 31, 2020",Actual,2020-03-31,March 2020,2020-03-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,eCardioCovid19,,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic",Recruiting,NA,N/A,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"If this platform will be functional, we are willing to provide the system and protocols and know-how to other centers in Romania.",2020-04-03T09:15:54Z,2020-04-03T09:15:54Z,Other,Tele-medicine platform,"Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).",1,Recruiting|Recruiting,Medical Sciences Academy|University of Medicine and Pharmacy Gr T Popa,Bucharest|Iasi,|,|700503,Romania|Romania,2
NCT04320238,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:19:19Z,2020-04-03T09:19:19Z,Drug|Drug,recombinant human interferon Alpha-1b|thymosin alpha 1,"recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.|thymosin alpha 1 subcutaneous injection 1 time per week.",2,Recruiting,Taihe Hospital,Shiyan,Hubei,,China,1
NCT04319731,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-22,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"March 20, 2021",Anticipated,2021-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NA,,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Not yet recruiting,NA,Early Phase 1,10,Anticipated,University of Utah,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:19:38Z,2020-04-03T09:19:38Z,Biological,Human Amniotic Fluid,Administration of amniotic fluid in SARS-CoV-2 positive patients,1,NA,NA,NA,NA,NA,NA,NA
NCT04330690,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"May 18, 2022",Anticipated,2022-05-18,"March 18, 2022",Anticipated,2022-03-18,NA,Interventional,CATCO,,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients","Active, not recruiting",NA,Phase 2,440,Anticipated,Sunnybrook Health Sciences Centre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Unknown and variable,NA,NA,Yes,"As per World Health Organization policies on data sharing in a Public Health Emergency, any clinical trial outcome data will be shared at the earliest possible opportunity. In addition, given the nature of this protocol, being performed across regions, the DSMB may access other regions trials, and possibly recommend alterations in study design based on accumulating data, through a centralized data repository being built under the auspices of the World Health Organization.
Data Sharing for Secondary Research Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de-identification through expert determination. The SAP and Analytic Code will also be made available. This data will be available immediately following publication, with no end date, as part of data sharing requirements from journals and funding agencies.",2020-04-03T09:12:50Z,2020-04-03T09:12:50Z,Drug,Lopinavir/ritonavir,"Lopinavir/ritonavir will be administered 400 mg/100 mg orally (or weight based dose adjustment for children) for a 14-day course, or until discharge from hospital, whichever occurs first",1,,Sunnybrook Health Sciences Centre,Toronto,Ontario,M4N3M5,Canada,1
NCT04328961,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-29,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-29,2020-04-01,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 PEP,"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Not yet recruiting,NA,Phase 1,2000,Anticipated,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2020-04-03T09:13:55Z,2020-04-03T09:13:55Z,Drug|Drug,Hydroxychloroquine Sulfate|Ascorbic Acid,Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.,2,||,"NYU Langone Health|University of Washington, Coordinating Center|UW Virology Research Clinic",New York|Seattle|Seattle,New York|Washington|Washington,10016|98104|98104,United States|United States|United States,3
NCT04328129,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-27,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Interventional,EPI-COVID-19,,Household Transmission Investigation Study for COVID-19 in French Guiana,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana,Recruiting,NA,N/A,450,Anticipated,Institut Pasteur,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:14:23Z,2020-04-03T09:14:23Z,Procedure,Human biological samples,"Blood sample
Nasopharyngeal swab.",1,Enrolling by invitation|Recruiting,Centre Hospitalier AndrÃ©e Rosemon|Institut Pasteur de la Guyane,Cayenne|Cayenne,|,|,French Guiana|French Guiana,2
NCT04323345,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 25, 2020",Anticipated,2020-03-25,March 2020,2020-03-31,"May 10, 2020",Anticipated,2020-05-10,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,NA,,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Not yet recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:17:23Z,2020-04-03T09:17:23Z,Dietary Supplement|Other,Natural Honey|Standard Care,Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.,2,,Mahmoud Tantawy,Cairo,,,Egypt,1
NCT04323228,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"October 30, 2020",Anticipated,2020-10-30,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,ONSCOVID19,,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial,Not yet recruiting,NA,Phase 4,30,Anticipated,King Saud University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,starting 6 months after publication.,Access will be available for any researcher interested in this type of research on considerable consent.,NA,Yes,all IPD that underlie results in a publication will be shared,2020-04-03T09:17:29Z,2020-04-03T09:17:29Z,Dietary Supplement|Dietary Supplement,"oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|isocaloric/isonutrigenous ONS","the intervention group will receive a commercially available anti-inflammatory/antioxidant ONS, which will be given to patients with COVID-19 in the morning 3 hours after breakfast.|The placebo group will receive an isocaloric/isonutrigenous ONS at the same time in the same shape/size/color of the cans.",2,NA,NA,NA,NA,NA,NA,NA
NCT04322682,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-26,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,COVID-19,,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,NA,Phase 3,6000,Anticipated,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:17:48Z,2020-04-03T09:17:48Z,Drug|Drug,Colchicine|Placebo oral tablet,"Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.",2,Recruiting,Montreal Heart Institute,Montreal,Quebec,H1T 1C8,Canada,1
NCT04322396,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"March 31, 2021",Anticipated,2021-03-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,ProPAC-COVID,,Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19,"Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Not yet recruiting,NA,Phase 4,226,Anticipated,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:17:58Z,2020-04-03T09:17:58Z,Drug|Drug|Drug|Drug,Azithromycin|Hydroxychloroquine|Placebo oral tablet|Placebo oral tablet,Azithromycin|Hydroxychloroquine|Placebo Azithromycin|Placebo Hydroxychloroquine,4,NA,NA,NA,NA,NA,NA,NA
NCT04322344,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,add-on-COV2,,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:18:00Z,2020-04-03T09:18:00Z,Drug|Drug,standard therapy|Escin,antiviral drugs|treatment with escin or escinate sodium,2,Recruiting,Luca Gallelli,Catanzaro,,88100,Italy,1
NCT04321616,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,"March 26, 2020",Anticipated,2020-03-26,March 2020,2020-03-31,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Not yet recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2020-04-03T09:18:27Z,2020-04-03T09:18:27Z,Drug|Drug|Other,Hydroxychloroquine|Remdesivir|(Standard of Care) SoC,Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 600 mg x 2 loading dose followed by 200 mg x 3 every day for 10 days.|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization up to a in 9 days10 days total course. A loading dose of 200 mg at inclusion will be given.|The standard of care will be supplied to all patients not receiving a drug intervention.,3,NA,NA,NA,NA,NA,NA,NA
NCT04321421,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,COV19-PLASMA,,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,"Active, not recruiting",NA,N/A,49,Anticipated,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,will be decided,2020-04-03T09:18:34Z,2020-04-03T09:18:34Z,Other,hyperimmune plasma,administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5,1,,Catherine Klersy,Pavia,PV,27100,Italy,1
NCT04321278,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-30,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients,Recruiting,NA,Phase 3,440,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:18:40Z,2020-04-03T09:18:40Z,Drug|Drug,Hydroxychloroquine + azithromycin|Hydroxychloroquine,"Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.",2,Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting,"Instituto de Cardiologia do Distrito Federal|FundaÃ§Ã£o Social Rural de Colatina|Hospital Vera Cruz AS|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda|Universidade Estadual de Londrina|Hospital UniversitÃ¡rio Onofre Lopes|Irmandade da Santa Casa de Misericordia de Porto Alegre|Maestri E Kormann Consultoria Medico-Cientifica|Sociedade Literaria e Caritativa Santo Agostinho|FundaÃ§Ã£o Pio XII|Santa Casa de Misericordia de Votuporanga|Hospital Israelita Albert Einstein|AMICO Saude LTDA|Associacao Beneficente Siria|Prevent Senior Private Operadora de Saude Ltda|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Santa Casa de MisericÃ³rdia|Secretaria de SaÃºde do Estado de SÃ£o Paulo|Serv Social da Industria do papel, papelÃ£o e cortiÃ§a do estado de SP|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs|Universidade Federal de SÃ£o Paulo",BrasÃ­lia|Colatina|Belo Horizonte|PoÃ§os De Caldas|Londrina|Natal|Porto Alegre|Blumenau|CriciÃºma|Barretos|Votuporanga|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,Distrito Federal|Espirito Santo|Minas Gerais|Minas Gerais|ParanÃ¡|Rio Grande Do Norte|Rio Grande Do Sul|Santa Catarina|Santa Catarina|SÃ£o Paulo|SÃ£o Paulo|||||||||||,|||||||||||05652-900||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,22
NCT04321096,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-24,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CamoCO-19,,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Not yet recruiting,NA,Phase 1/Phase 2,180,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2020-04-03T09:18:46Z,2020-04-03T09:18:46Z,Drug|Drug,Camostat Mesilate|Placebo oral tablet,Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2|Placebo,2,||,"Department of Infectious Diseases|Department for Infectious Diseases, Aarhus University Hospital|Dept. of Infectious Diseases, Odense University Hospital",Aalborg|Aarhus N|Odense,||,|8200|5000,Denmark|Denmark|Denmark,3
NCT04320615,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-23,NA,NA,2020-03-26,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"April 3, 2020",Anticipated,2020-04-03,March 2020,2020-03-31,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Not yet recruiting,NA,Phase 3,330,Anticipated,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com).
Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2020-04-03T09:19:06Z,2020-04-03T09:19:06Z,Drug|Drug,Tocilizumab (TCZ)|Placebo,Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.,2,NA,NA,NA,NA,NA,NA,NA
NCT04327349,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-24,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,N/A,30,Anticipated,Mazandaran University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:14:56Z,2020-04-03T09:14:56Z,Biological,Convalescent Plasma,Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU,1,,"Imam Khomeini Hospital, Mazandaran University of Medical Sciences",Sari,Mazandaran,4816633131,"Iran, Islamic Republic of",1
NCT04326920,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-24,NA,NA,2020-03-31,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"March 24, 2020",Actual,2020-03-24,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,SARPAC,,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Recruiting,NA,Phase 4,80,Anticipated,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-03T09:15:14Z,2020-04-03T09:15:14Z,Drug|Other,Sargramostim|Control,Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration|Standard of care,2,Recruiting|Recruiting,AZ Sint Jan Brugge|University Hospital Ghent,Brugge|Gent,|,8000|9000,Belgium|Belgium,2
NCT04323800,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-24,NA,NA,2020-03-31,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,January 2023,Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CSSC-001,,Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19,"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19",Not yet recruiting,NA,Phase 2,150,Anticipated,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2020-04-03T09:17:07Z,2020-04-03T09:17:07Z,Biological|Biological,Anti- SARS-CoV-2 Plasma|SARS-CoV-2 non-immune Plasma,SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and was found to have a titer of neutralizing antibody >1:64)|Standard plasma collected prior to December 2019,2,NA,NA,NA,NA,NA,NA,NA
NCT04322773,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-24,NA,NA,2020-03-26,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"March 25, 2020",Anticipated,2020-03-25,March 2020,2020-03-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,TOCIVID,,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial",Not yet recruiting,NA,Phase 2,200,Anticipated,Frederiksberg University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-04-03T09:17:44Z,2020-04-03T09:17:44Z,Drug|Drug|Drug|Other,RoActemra iv|RoActemra sc|Kevzara sc|Standard medical care,single dose treatment with tocilizumab 400 mg intravenously|single dose treatment with tocilizumab 2 x 162 mg subcutaneously|single dose treatment with sarilumab 1 x 200 mg subcutaneously|management as usual,4,,Bispebjerg-Frederiksberg Hospital,Copenhagen,,2000,Denmark,1
NCT04322565,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Colchicine Efficacy in COVID-19 Pneumonia,COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA,Not yet recruiting,NA,Phase 2,100,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data will be avaliable from June 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2020-04-03T09:17:51Z,2020-04-03T09:17:51Z,Drug,Colchicine,Cochicine 1mg/day,1,NA,NA,NA,NA,NA,NA,NA
NCT04322123,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,Coalition-I,,Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus,"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients",Not yet recruiting,NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:18:08Z,2020-04-03T09:18:08Z,Drug|Drug,Hydroxychloroquine Oral Product|Hydroxychloroquine + azithromycin,Hydroxychloroquine 400 mg BID|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day,2,|||||||||||||||||||||||||||||||,Hospital Geral ClÃ©riston Andrade|Hospital Ana Nery - HAN/SESAB|HHospital SAMUR|Hospital Geral de VitÃ³ria da Conquista|Hospital de BrasÃ­lia|Instituto de Cardiologia do Distrito Federal|Hospital Maternidade SÃ£o JosÃ© - UNESC - FundaÃ§Ã£o Social Rural de Colatina|Hospital Vila da Serra|Santa Casa de MisericÃ³rdia de SÃ£o JoÃ£o Del Rei|AssociaÃ§Ã£o EvangÃ©lica Beneficente de Londrina - Hospital EvangÃ©lico de Londrina|Instituto Estadual do CÃ©rebro Paulo Niemeyer|Hospital Geral de Caxias do Sul|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o Francisco - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o JosÃ©|Hospital BaÃ­a Sul - BaÃ­a Sul Medical Center|Hospital Nereu Ramos|Centro Hospitalar Unimed|Hospital de Amor - Unidade Barretos (FundaÃ§Ã£o PIO XII)|Faculdade de Medicina de SÃ£o JosÃ© do Rio Preto|AC Camargo Cancer Center - FundaÃ§Ã£o Antonio Prudente|Casa de SaÃºde Santa Marcelina|Hospital Albert Einstein|Hospital BeneficÃªncia Portuguesa - Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia|Hospital BP Mirante - Real e BenemÃ©rita|Hospital da Luz - Amico SaÃºde LTDA|Hospital das ClÃ­nicas da FMUSP|Hospital do Servidor PÃºblico Estadual - HSPE - IAMSPE|Hospital SÃ£o Paulo - UNIFESP|Hospital SÃ­rio-LibanÃªs|Hospital SEPACO|Hospital das ClÃ­nicas da Faculdade de Medicina da USP - RibeirÃ£o Preto,Feira De Santana|Salvador|VitÃ³ria Da Conquista|VitÃ³ria Da Conquista|Brasilia|BrasÃ­lia|Colatina|Nova Lima|SÃ£o JoÃ£o Del Rei|Londrina|Rio De Janeiro|Caxias do Sul|Porto Alegre|Porto Alegre|Criciuma|FlorianÃ³polis|FlorianÃ³polis|Joinville|Barretos|SÃ£o JosÃ© do Rio Preto|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|RibeirÃ£o Preto,BA|BA|BA|BA|DF|DF|ES|MG|MG|PR|RJ|RS|RS|RS|SC|SC|Sc|SC|SP|SP|SP|SP|SP|SP|SP|SP|SP|SP|SP|SP|S|SÃ£o Paulo,|||||||||||||||||||||||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,32
NCT04321993,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,July 2021,Anticipated,2021-07-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Not yet recruiting,NA,Phase 2,1000,Anticipated,Nova Scotia Health Authority,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:18:13Z,2020-04-03T09:18:13Z,Drug|Drug|Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate|Baricitinib (janus kinase inhibitor)|Sarilumab (anti-IL-6 receptor),"Lopinavir/ritonavir tablet 200mg/50mg 2 tables by mouth, every 12 hours for 10 days|Hydroxychloroquine sulfate sulfate tablet 200 mg 2 tablets by mouth, every 12 hours for 10 days|Baricitinib 2 mg po daily for 10 days|Sarilumab 200mg subcutaneous injection once",4,NA,NA,NA,NA,NA,NA,NA
NCT04328285,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 30, 2020",Anticipated,2020-03-30,March 2020,2020-03-31,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVIDAXIS,,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial,Not yet recruiting,NA,Phase 3,1200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:14:18Z,2020-04-03T09:14:18Z,Drug|Drug|Drug|Drug,Hydroxychloroquine|Placebo of Hydroxychloroquine|Lopinavir and ritonavir|Placebo of LPV/r Tablets,Hydroxychloroquine Oral Tablets|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets|LPV/r Oral Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets,4,||,CHU d'Angers|AP-HP - HÃ´pital Bichat|CHU de Saint-Etienne,Angers|Paris|Saint-Ã‰tienne,||,||,France|France|France,3
NCT04328272,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-31,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"June 28, 2020",Anticipated,2020-06-28,"May 28, 2020",Anticipated,2020-05-28,NA,Interventional,Covid,,Effectiveness of Hydroxychloroquine in Covid-19 Patients,Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study,Not yet recruiting,NA,Phase 3,75,Anticipated,"Ayub Medical College, Abbottabad",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,as each individual will have his/her own coded file. the required data from each will be extracted and will be made available in soft copies,2020-04-03T09:14:18Z,2020-04-03T09:14:18Z,Drug|Drug|Dietary Supplement,Hydroxychloroquine 200 Mg Oral Tablet|Azithromycin 500Mg Oral Tablet|Glucose tablets,Hydroxychloroquine administered orally with water|Azithromycin administered orally with water|administered orally with water,3,,Ayub Teaching Institution,AbbottÄbÄd,K.p.k,00532,Pakistan,1
NCT04327505,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"April 25, 2020",Anticipated,2020-04-25,March 2020,2020-03-31,"December 31, 2022",Anticipated,2022-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,COVID-19-HBO,,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,"Safety and Efficacy of Hyperbaric Oxygen for Improvement of Acute Respiratory Distress Syndrome in Adult Patients With COVID-19; a Randomized, Controlled, Open Label, Multicentre Clinical Trial",Not yet recruiting,NA,Phase 2/Phase 3,200,Anticipated,Karolinska University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:14:49Z,2020-04-03T09:14:49Z,Drug,Hyperbaric oxygen,"2.4 Bar (2.4 ATA), 30 min (excluding compression/recompression)",1,NA,NA,NA,NA,NA,NA,NA
NCT04327206,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-04-01,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"March 30, 2022",Anticipated,2022-03-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,BRACE,,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial,Recruiting,NA,Phase 3,4170,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2020-04-03T09:15:01Z,2020-04-03T09:15:01Z,Drug,BCG Vaccine,"Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection",1,Recruiting,Royal Children's Hospital,Melbourne,Victoria,3108,Australia,1
NCT04326452,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 27, 2020",Anticipated,2020-03-27,March 2020,2020-03-31,"June 1, 2020",Anticipated,2020-06-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,N/A,15,Anticipated,TMC HealthCare,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:15:31Z,2020-04-03T09:15:31Z,Device,bidirectional oxygenation mouthpiece,Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.,1,Recruiting|Recruiting|Recruiting,TMC HealthCare|Stanford University|Emory Saint Joseph's Hospital,Tucson|Stanford|Atlanta,Arizona|California|Georgia,85712|94305|30342,United States|United States|United States,3
NCT04325893,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-30,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,HYCOVID,,"Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study","Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study",Not yet recruiting,NA,Phase 3,1300,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:15:53Z,2020-04-03T09:15:53Z,Drug|Drug,Hydroxychloroquine|Placebo,"First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and the treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.|The first dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and the treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.",2,NA,NA,NA,NA,NA,NA,NA
NCT04325061,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-31,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,DEXA-COVID19,,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Not yet recruiting,NA,Phase 4,200,Anticipated,Dr. Negrin University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:16:24Z,2020-04-03T09:16:24Z,Drug,Dexamethasone,"Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization",1,||||||||||||||||,"Department of Anesthesia, Hospital Universitario de Cruces|Intensive Care Unit, Hospital Universitario de Cruces|Department of Anesthesia, Hospital Clinic|Intensive Care Unit, Hospital General de Ciudad Real|Hospital Universitario Dr. Negrin|Department of Anesthesia, Hospital Universitario La Princesa|Intensive Care Unit, Hospital Universitario La Princesa|Intensive Care Unit, Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az|Department of Anesthesia, Hospital Universitario La Paz|Intensive Care Unit, Hospital Universitario La Paz|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca|Department of Anesthesia, Hospital Unversitario Montecelo|Department of Anesthesia, Hospital Clinico Universitario|Intensive Care Unit, Hospital Clinico Universitario|Intensive Care Unit, Hospital Universitario La Fe|Department of Anesthesia, Hospital ClÃ­nico Universitario|Intensive Care Unit, Hospital Universitario RÃ­o Hortega",Barakaldo|Barakaldo|Barcelona|Ciudad Real|Las Palmas de Gran Canaria|Madrid|Madrid|Madrid|Madrid|Madrid|Murcia|Pontevedra|Valencia|Valencia|Valencia|Valladolid|Valladolid,Vizcaya|Vizcaya|||||||||||||||,48903|48903|08036|13005|35019|28006|28006|28040|28046|28046|30120|36071|46010|46010|46026|47003|47012,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,17
NCT04324996,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Chongqing Public Health Medical Center,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:16:26Z,2020-04-03T09:16:26Z,Biological,"NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells",The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.,1,Recruiting,Chongqing Public Health Medical Center,Chongqing,,,China,1
NCT04324528,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"November 26, 2020",Anticipated,2020-11-26,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,CYCOV,,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,NA,N/A,30,Anticipated,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:16:42Z,2020-04-03T09:16:42Z,Device|Device,vv-ECMO + cytokine adsorption (Cytosorb adsorber)|vv-ECMO only (no cytokine adsorption),in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)|COVID-19-diseased treated with vv-ECMO,2,Recruiting,University Clinic Freiburg,Freiburg,,79108,Germany,1
NCT04324489,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-31,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"March 6, 2020",Actual,2020-03-06,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 25, 2020",Anticipated,2020-04-25,NA,Interventional,NA,,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Recruiting,NA,N/A,4,Anticipated,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-03T09:16:44Z,2020-04-03T09:16:44Z,Drug,DAS181,"Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.",1,Recruiting,Renmin Hospital of Wuhan University,Wuhan,Hubei,,China,1
NCT04324463,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,ACT COVID19,,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Not yet recruiting,NA,Phase 3,1500,Anticipated,Population Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:16:44Z,2020-04-03T09:16:44Z,Drug|Drug,Azithromycin|Chloroquine,oral medication|oral medication,2,,Hamilton Health Sciences,Hamilton,Ontario,L8L2X2,Canada,1
NCT04324073,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-31,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,CORIMUNO-SARI,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Recruiting,NA,Phase 2/Phase 3,240,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-03T09:16:57Z,2020-04-03T09:16:57Z,Drug,Sarilumab,(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1,1,Recruiting|Recruiting|Recruiting|Not yet recruiting,Kremlin Bicetre hospital APHP|Cochin Aphp|HEGP|NECKER Hospital,Le Kremlin-BicÃªtre|Paris|Paris|Paris,Ile De France|Ile De France|Ile De France|,|||75005,France|France|France|France,4
NCT04324021,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNÎ³) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.",Not yet recruiting,NA,Phase 2/Phase 3,54,Anticipated,Swedish Orphan Biovitrum,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:16:59Z,2020-04-03T09:16:59Z,Biological|Biological,Emapalumab|Anakinra,I.v infusion every third day|Daily i.v infusion,2,|||,"ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta IntensitÃ  di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani",Brescia|Milano|Parma|Roma,|||,|||,Italy|Italy|Italy|Italy,4
NCT04323631,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,Not yet recruiting,NA,Early Phase 1,1116,Anticipated,Rambam Health Care Campus,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:17:13Z,2020-04-03T09:17:13Z,Drug|Other,Hydroxychloroquine|The control group will not receive hydroxychloroquine,Oral|The control group will not receive hydroxychloroquine,2,NA,NA,NA,NA,NA,NA,NA
NCT04329533,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-31,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"July 30, 2020",Anticipated,2020-07-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,"Effects of Using Mobile App on Perceived Stress During Coronavirus (""COVID 19"") Pandemic","Effects of a Mobile Meditation App on Stress During Coronavirus (""COVID-19"") Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial",Not yet recruiting,NA,N/A,150,Anticipated,University of Arizona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:13:34Z,2020-04-03T09:13:34Z,Other,"""Calm"" is a mindfulness meditation mobile app","Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the ""Calm"" app, can be used to help manage stress, especially during this uncertain time.",1,NA,NA,NA,NA,NA,NA,NA
NCT04327401,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-30,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,CODEX,,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CODEX (Alliance Covid-19 Brasil III)",Not yet recruiting,NA,Phase 3,290,Anticipated,Hospital Sirio-Libanes,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:14:52Z,2020-04-03T09:14:52Z,Drug,Dexamethasone,Dexamethasone administration for 10 consecutive days after randomization.,1,||||||||||||||||||||,Hospital Ana Nery|Instituto de Cardiologia do Distrito Federal|FundaÃ§Ã£o Social Rural de Colatina|Hospital Vera Cruz AS|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda|Universidade Estadual de Londrina|Eurolatino Natal Pesquisas MÃ©dicas Ltda|Irmandade da Santa Casa de Misericordia de Porto Alegre|Maestri E Kormann Consultoria Medico-Cientifica|Sociedade Literaria e Caritativa Santo Agostinho|FundaÃ§Ã£o Pio XII|Santa Casa de Misericordia de Votuporanga|Associacao Beneficente Siria|Hospital das ClÃ­nicas da Faculdade de Medicina de RibeirÃ£o Preto da USP - HCFMRP|Hospital Israelita Albert Einstein|Prevent Senior Private Operadora de Saude Ltda|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Santa Casa de MisericÃ³rdia|Secretaria de SaÃºde do Estado de SÃ£o Paulo|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs|Universidade Federal de SÃ£o Paulo,Salvador|BrasÃ­lia|Colatina|Belo Horizonte|PoÃ§os De Caldas|Londrina|Natal|Porto Alegre|Blumenau|CriciÃºma|Barretos|Votuporanga|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,Bahia|Distrito Federal|EsoÃ­rito Santo|Minas Gerais|Minas Gerais|ParanÃ¡|Rio Grande Do Norte|Rio Grande Do Sul|Santa Catarina|Santa Catarina|SÃ£o Paulo|SÃ£o Paulo|||||||||,||||||||||||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,21
NCT04327388,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-04-01,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"March 28, 2020",Actual,2020-03-28,April 2020,2020-04-30,June 2021,Anticipated,2021-06-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Sarilumab COVID-19,"An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-04-03T09:14:53Z,2020-04-03T09:14:53Z,Drug|Drug,Sarilumab SAR153191|Placebo,Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion|Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion,2,Recruiting,2500001,Bordeaux Cedex,,,France,1
NCT04326790,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-31,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,GRECCO-19,,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Not yet recruiting,NA,Phase 2,180,Anticipated,National and Kapodistrian University of Athens,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:15:19Z,2020-04-03T09:15:19Z,Drug|Drug,Colchicine|Standard treatment,"Low-dose colchicine treatment, 0.5 mg bid|Standard treatment",2,NA,NA,NA,NA,NA,NA,NA
NCT04326426,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-27,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-30,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,COVIDL1: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"COVIDL1: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Not yet recruiting,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:15:32Z,2020-04-03T09:15:32Z,Drug|Drug,Tradipitant|Placebo,Neurokinin-1 antagonist|Matching placebo,2,NA,NA,NA,NA,NA,NA,NA
NCT04326114,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-27,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-30,Actual,"April 26, 2020",Anticipated,2020-04-26,March 2020,2020-03-31,"October 12, 2020",Anticipated,2020-10-12,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,NA,,Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19,Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial,Not yet recruiting,NA,N/A,240,Anticipated,Universidad Complutense de Madrid,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:15:45Z,2020-04-03T09:15:45Z,Device|Device,Inspiratory training device|Expiratory training device,Inspiratory training by a Power-breath device|Expiratory training a Winner-flow device,2,NA,NA,NA,NA,NA,NA,NA
NCT04326075,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-28,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-28,2020-03-31,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"October 5, 2020",Anticipated,2020-10-05,NA,Interventional,EC-COVID-RCT,,Early CPAP in COVID Patients With Respiratory Failure.,EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial,Not yet recruiting,NA,N/A,900,Anticipated,Mario Negri Institute for Pharmacological Research,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:15:46Z,2020-04-03T09:15:46Z,Device,CPAP treatment,"CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.",1,NA,NA,NA,NA,NA,NA,NA
NCT04326036,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-30,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,GARM-COVID19,,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,Healeon Medical Inc,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,In discussion phase,2020-04-03T09:15:47Z,2020-04-03T09:15:47Z,Procedure|Device|Procedure|Drug|Drug,Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Centricyte 1000|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Liberase Enzyme (Roche)|Sterile Normal Saline for Intravenous Use,"Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration|Sterile Collagenase Blend to separate cSVF from the AD-SVF|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter",5,,"Robert W. Alexander, MD, FICS, LLC",Stevensville,Montana,59870,United States,1
NCT04325906,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-27,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-30,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Not yet recruiting,NA,N/A,162,Anticipated,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:15:52Z,2020-04-03T09:15:52Z,Device|Procedure,high flow nasal cannula (HFNC)|Prone positioning (PP),"HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (â‰¤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.",2,|,Rush University Medical Center|Medical College of Wisconsin,Chicago|Wauwatosa,Illinois|Wisconsin,60612|53226,United States|United States,2
NCT04325672,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,,Convalescent Plasma to Limit Coronavirus Associated Complications,"Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19",Not yet recruiting,NA,Phase 2,20,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:16:01Z,2020-04-03T09:16:01Z,Biological,Convalescent Plasma,Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.,1,,Mayo Clinic in Rochester,Rochester,Minnesota,55905,United States,1
NCT04325633,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,"March 27, 2020",Anticipated,2020-03-27,March 2020,2020-03-31,"June 27, 2021",Anticipated,2021-06-27,"April 27, 2021",Anticipated,2021-04-27,NA,Interventional,ENACOVID,,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Not yet recruiting,NA,Phase 3,584,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:16:02Z,2020-04-03T09:16:02Z,Drug|Drug,1: Naproxen|2: Standard of care,Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)|Standard of care,2,NA,NA,NA,NA,NA,NA,NA
NCT04324190,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,DISPOSE,,DIgital Online SuPport for COVID-19 StrEss,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic,Not yet recruiting,NA,N/A,600,Anticipated,International Psychoanalytic University Berlin,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:16:54Z,2020-04-03T09:16:54Z,Behavioral|Behavioral,Guided online support program|WHO recommendations (waiting condition),"Guided online support program consisting of several modules; Module ""General information ..."" is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)|During the waiting period, a german translation of the WHO recommendations ""Coping with stress during the 2019-nCoV outbreak"" is provided",2,,Selfapy GmbH,Berlin,,10435,Germany,1
NCT04331899,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-27,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 15, 2020",Anticipated,2020-04-15,March 2020,2020-03-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,COVID-Lambda,,Mild COVID-19 Peginterferon Lambda,"A Phase 2 Randomized, Open Label Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19",Not yet recruiting,NA,Phase 2,120,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No current plan to share the data.,2020-04-03T09:12:11Z,2020-04-03T09:12:11Z,Drug|Other,Peginterferon Lambda-1a|Standard of Care Treatment,Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose|Standard of Care Treatment for COVID-19 Infection,2,NA,NA,NA,NA,NA,NA,NA
NCT04328493,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-27,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,VICO,,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Not yet recruiting,NA,Phase 2,250,Anticipated,"Oxford University Clinical Research Unit, Vietnam",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:14:11Z,2020-04-03T09:14:11Z,Drug,Chloroquine phosphate,"Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.
A loading dose of 1200mg chloroquine phosphate base, administered with food where possible, is given on the first 24 hours after randomization. Following, patients will receive a dose of chloroquine phosphate base of 300mg once daily for 9 days (unless they are <60Kg, when the dose will be reduced following its pharmacokinetic properties).
The total duration of treatment with Chloroquine will be 10 days",1,||||,National Hospital for Tropical Diseases|Can Gio COVID Hospital|Cho Ray Hospital|Cu Chi COVID Hospital|Hospital for Tropical Diseases,Hanoi|Ho Chi Minh City|Ho Chi Minh City|Ho Chi Minh City|Ho Chi Minh City,||||,||||,Vietnam|Vietnam|Vietnam|Vietnam|Vietnam,5
NCT04328467,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-27,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Not yet recruiting,NA,Phase 3,3500,Anticipated,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:14:12Z,2020-04-03T09:14:12Z,Drug|Other,Hydroxychloroquine|Placebo,Hydroxychloroquine; 200mg tablet; oral|Placebo; tablet; oral,2,,University of Minnesota,Minneapolis,Minnesota,55455,United States,1
NCT04328441,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-27,NA,NA,2020-03-27,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"December 25, 2020",Anticipated,2020-12-25,"October 25, 2020",Anticipated,2020-10-25,NA,Interventional,BCG-CORONA,,"REDUCING HEALTH CARE WORKERS ABSENTEEISM IN SARS-CoV-2 PANDEMIC THROUGH BACILLUS CALMETTE-GUÃ‰RIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL","REDUCING HEALTH CARE WORKERS ABSENTEEISM IN SARS-CoV-2 PANDEMIC BY ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÃ‰RIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL",Recruiting,NA,Phase 3,1000,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,The results of this study will be disclosed unreservedly at the end of the study.,2020-04-03T09:14:13Z,2020-04-03T09:14:13Z,Drug,BCG Vaccine,"Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis",1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Jeroen Bosch ziekenhuis|Canisius Wilhelmina Ziekenhuis|Radboud UMC|Sint Maartenskliniek|Noordwest Ziekenhuisgroep locatie Alkmaar|Hagaziekenhuis|Leiden University Medical Center|Erasmus Medical Center|University Medical Center Utrecht,Den Bosch|Nijmegen|Nijmegen|Nijmegen|Alkmaar|Den Haag|Leiden|Rotterdam|Utrecht,Brabant|Gelderland|Gelderland|Gelderland|Noord Holland|Zuid-Holland|Zuid-Holland|Zuid-Holland|,||||||||,Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands|Netherlands,9
NCT04328012,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-27,NA,NA,2020-03-27,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,COVID MED,,Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial),Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial),Not yet recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Bassett Healthcare,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-03T09:14:30Z,2020-04-03T09:14:30Z,Drug|Drug|Drug|Drug,Placebos|lopinavir/ritonavir|Losartan|Hydroxychloroquine Sulfate,"administered 14 days|administered for 5 day minimally, up to 14 days if supply available|administered for 5 day minimally, up to 14 days if supply available|administered for 5 day minimally, up to 14 days if supply available",4,NA,NA,NA,NA,NA,NA,NA
NCT04332042,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-28,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 10, 2020",Anticipated,2020-07-10,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,NA,,TOFAcitinib in SARS-CoV2 Pneumonia,TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia,Not yet recruiting,NA,Phase 2,50,Anticipated,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:07Z,2020-04-03T09:12:07Z,Drug,Tofacitinib,Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days,1,,Ospedali Riuniti di Ancona,Ancona,Marche,60126,Italy,1
NCT04329195,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-28,NA,NA,2020-03-28,2020-03-28,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-28,2020-04-01,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,ACORES-2,,ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemia,ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study,Not yet recruiting,NA,Phase 3,554,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:13:44Z,2020-04-03T09:13:44Z,Drug|Drug,1: discontinuation of RAS blocker therapy|2: continuation of RAS blocker therapy,discontinuation of RAS blocker therapy|continuation of RAS blocker therapy,2,NA,NA,NA,NA,NA,NA,NA
NCT04331054,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-29,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,INHASCO,,Protective Role of Inhaled Steroids for Covid-19 Infection,Protective Role of Inhaled Steroids for Covid-19 Infection,Not yet recruiting,NA,Phase 3,436,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:12:39Z,2020-04-03T09:12:39Z,Drug|Other,2: Usual practice + SYMBICORT RAPIHALER|1: Usual practice,2 puffs bid during 30 days by inhalation|Usual practice,2,,HÃ´pital Bichat - Service de Pneumologie,Paris,,75010,France,1
NCT04329611,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-29,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 8, 2020",Anticipated,2020-04-08,March 2020,2020-03-31,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Hydroxychloroquine to Prevent Covid19 Pneumonia (ALBERTA HOPE-Covid19),"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease",Not yet recruiting,NA,Phase 3,1660,Anticipated,University of Calgary,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,24 months after study close out.,pending.,NA,Yes,NA,2020-04-03T09:13:31Z,2020-04-03T09:13:31Z,Drug,Hydroxychloroquine,COVID19,1,,University of Calgary/Foothills Medical Centre,Calgary,Alberta,T2N 2T9,Canada,1
NCT04329572,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-29,NA,NA,2020-03-31,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"April 3, 2020",Anticipated,2020-04-03,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,"Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus",Not yet recruiting,NA,Early Phase 1,400,Anticipated,Azidus Brasil,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-04-03T09:13:32Z,2020-04-03T09:13:32Z,Drug|Drug,Hydroxychloroquine Sulfate|Azithromycin Tablets,All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.|All patients included in the study will receive AZT 500 mg per day for 5 days.,2,NA,NA,NA,NA,NA,NA,NA
NCT04332380,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CP-COVID-19,,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Not yet recruiting,NA,Phase 2,10,Anticipated,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:11:56Z,2020-04-03T09:11:56Z,Drug,Plasma,"Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.",1,,Universidad del Rosario,Bogota,Cundinamarca,11100,Colombia,1
NCT04332107,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"July 30, 2021",Anticipated,2021-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,ACTION,,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,Not yet recruiting,NA,Phase 3,2271,Anticipated,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-04-03T09:12:05Z,2020-04-03T09:12:05Z,Drug|Drug,Azithromycin|Placebos,Participants will be shipped a single 1 g dose of oral azithromycin|Participants will be shipped a dose of matching placebo,2,,University of California San Francisco,San Francisco,California,94143,United States,1
NCT04332081,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Hyperbaric Oxygen for COVID-19 Patients,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19,Not yet recruiting,NA,N/A,40,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,Immediately following publication. No end date.,"Requests should be directed to David.Lee@nyulangone.org and Scott.Gorenstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available immediately following publication, upon reasonable request by an investigator who proposes to use the data.",2020-04-03T09:12:06Z,2020-04-03T09:12:06Z,Device,hyperbaric oxygen therapy (HBOT),The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.,1,,NYU Winthrop Hospital,Mineola,New York,11501,United States,1
NCT04331600,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,QUARANTINE2020,,ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Effectiveness and Safety of Chloroquine Phosphate in Combination With Telemedicine in the Reduction of Risk of Disease-related Hospitalization or Death, in Ambulatory Patients With COVID-19 at Particular Risk of Serious Complications",Not yet recruiting,NA,Phase 4,400,Anticipated,Wroclaw Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:21Z,2020-04-03T09:12:21Z,Drug|Other,Chloroquine phosphate|Telemedicine,Oral chloroquine phosphate for 14 days|Telemedical supervision for 42 days,2,NA,NA,NA,NA,NA,NA,NA
NCT04331470,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-03-31,2020-03-31,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"May 20, 2020",Anticipated,2020-05-20,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,NA,,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease,Not yet recruiting,NA,Phase 2/Phase 3,30,Anticipated,Fasa University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,between 1 to 2 months after analyzing the raw data.,Results will be available in Journals.,http://journal.fums.ac.ir/en,Yes,All IPD that underlie results in a publication and is comply with ethics will be revealed.,2020-04-03T09:12:25Z,2020-04-03T09:12:25Z,Drug|Drug,Levamisole Pill + Budesonide+Formoterol inhaler|Lopinavir/Ritonavir + hydoxychloroquine,Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours,2,NA,NA,NA,NA,NA,NA,NA
NCT04330300,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-03-31,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"March 30, 2020",Actual,2020-03-30,March 2020,2020-03-31,"March 1, 2021",Anticipated,2021-03-01,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CORONACION,,Coronavirus ACEi/ARB Investigation,CORONAvirus Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers InvestigatiON: A Randomized Clinical Trial,Recruiting,NA,Phase 4,2414,Anticipated,"National University of Ireland, Galway, Ireland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:13:05Z,2020-04-03T09:13:05Z,Drug|Drug|Drug|Drug,Thiazide or Thiazide-like diuretics|Calcium Channel Blockers|ACE inhibitor|Angiotensin receptor blocker,Anti-hypertensive (Active Arm)|Anti-hypertensive (Active Arm)|Anti-hypertensive (Control Arm)|Anti-hypertensive (Control Arm),4,Recruiting,University Hospital Galway,Galway,,H91 YR71,Ireland,1
NCT04330144,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"March 30, 2022",Anticipated,2022-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial),A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial),Not yet recruiting,NA,Phase 3,2486,Anticipated,Gangnam Severance Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-03T09:13:13Z,2020-04-03T09:13:13Z,Drug|Other,Hydroxychloroquine as post exposure prophylaxis|Others(No intervention),1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po|No treatment. Close monitoring and quarantine.,2,NA,NA,NA,NA,NA,NA,NA
NCT04329923,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-03-30,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"December 1, 2021",Anticipated,2021-12-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,PATCH,,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Not yet recruiting,NA,Phase 2,400,Anticipated,University of Pennsylvania,,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,One year after study completion,Open access,NA,Yes,We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis,2020-04-03T09:13:20Z,2020-04-03T09:13:20Z,Drug|Drug|Drug|Drug,Hydroxychloroquine Sulfate 400 mg twice a day|Hydroxychloroquine Sulfate 600 mg twice a day|Hydroxychloroquine Sulfate 600 mg once a day|Placebo oral tablet,Antimalarial compound|Antimalarial compound|Antimalarial compound|Placebo,4,,University of Pennsylvania,Philadelphia,Pennsylvania,19104,United States,1
NCT04329832,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-03-30,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,HAHPS,,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial,Not yet recruiting,NA,Phase 2,300,Anticipated,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2020-04-03T09:13:24Z,2020-04-03T09:13:24Z,Drug|Drug,Hydroxychloroquine|Azithromycin,"Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min).|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization, the prior doses will count toward the 5-day total.",2,|,Intermountain Medical Center|University of Utah,Murray|Salt Lake City,Utah|Utah,84107|84112,United States|United States,2
NCT04328480,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-30,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,COLCOVID,,The ECLA PHRI COLCOVID Trial,The ECLA PHRI COLCOVID Trial,Not yet recruiting,NA,Phase 3,2500,Anticipated,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:14:11Z,2020-04-03T09:14:11Z,Drug|Other,Colchicine|Local standard of care,"The colchicine dosage schedule will vary according to the following scenarios:
In patients not receiving Lopinavir/Ritonavir
Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)
The next day 0.5 mg bid for 14 days or until discharge.
In patients receiving Lopinavir/Ritonavir
Loading dose of 0.5 mg (day 1)
After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.
Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir
Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.
Continue with 0.5 mg every 72 hours for 14 days or until discharge.
Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.|Local standard of care for COVID-19 SARS moderate /high-risk patients",2,NA,NA,NA,NA,NA,NA,NA
NCT04329520,"ClinicalTrials.gov processed this data on April 01, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Estimate,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Estimate,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,EPICOS,,EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarato/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,"Active, not recruiting",NA,Phase 3,4000,Anticipated,Effice Servicios Para la Investigacion S.L.,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:13:28Z,2020-04-02T09:13:28Z,Drug|Drug|Drug|Drug,Emtricitabine/tenofovir disoproxil|Hydroxychloroquine|Placebo: Emtricitabine/tenofovir disoproxil|Placebo: Hydroxychloroquine,"Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.|Placebo. Tablets similar in appearance to Emtricitabine/tenofovir disoproxil|Placebo. Tablets similar in appearance to Hydroxychloroquine",4,,Hospital Universitario RamÃ³n y Cajal,Madrid,,28034,Spain,1
NCT04332094,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-31,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,TOCOVID,,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)",Not yet recruiting,NA,Phase 2,276,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:12:05Z,2020-04-03T09:12:05Z,Drug|Drug|Drug,Tocilizumab|Hydroxychloroquine|Azithromycin,162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)|500 mg / day v.o. for 3 days,3,NA,NA,NA,NA,NA,NA,NA
NCT04331808,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIMUNO-TOC,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),Not yet recruiting,NA,Phase 2,240,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:12:14Z,2020-04-03T09:12:14Z,Drug,Tocilizumab,Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.,1,NA,NA,NA,NA,NA,NA,NA
NCT04331366,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Estimate,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,April 2020,Anticipated,2020-04-30,April 2020,Anticipated,2020-04-30,NA,Interventional,GO2 PEEP,,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Not yet recruiting,NA,N/A,5,Anticipated,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:28Z,2020-04-03T09:12:28Z,Device,GO2 PEEP MOUTHPIECE,"The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.",1,|,Emory University Hospital|Emory St. Joseph's Hospital,Atlanta|Atlanta,Georgia|Georgia,30322|30342,United States|United States,2
NCT04330638,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,COV-AID,,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Not yet recruiting,NA,Phase 4,342,Anticipated,"University Hospital, Ghent",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:52Z,2020-04-03T09:12:52Z,Other|Drug|Drug|Drug,Usual Care|Anakinra|Siltuximab|Tocilizumab,"Usual Care|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection",4,||||||||,AZ Sint-Jan Brugge|University Hospital Saint-Pierre|Erasmus University Hospital|University Hospital Saint-Luc|University Hospital Antwerp|Ziekenhuis Oost-Limurg|University Hospital Ghent|University Hospital Brussels|University Hospital LiÃ¨ge,Brugge|Brussels|Brussels|Brussels|Edegem|Genk|Gent|Jette|LiÃ¨ge,||||||||,8000|1000|1070|1200|2650|3600|9000|1090|4000,Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium|Belgium,9
NCT04330586,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,A Trial of Ciclesonide in Adults With Mild COVID-19,A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19,Not yet recruiting,NA,Phase 2,141,Anticipated,Korea University Guro Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:54Z,2020-04-03T09:12:54Z,Drug|Drug,Ciclesonide Metered Dose Inhaler [Alvesco]|Hydroxychloroquine,Ciclesonide 320ug oral inhalation q12h for 14 days|Hydroxychloroquine 400mg QD for 10 days,2,NA,NA,NA,NA,NA,NA,NA
NCT04330495,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"November 6, 2020",Anticipated,2020-11-06,"November 6, 2020",Anticipated,2020-11-06,NA,Interventional,NA,,"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection",Not yet recruiting,NA,Phase 4,800,Anticipated,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-03T09:12:57Z,2020-04-03T09:12:57Z,Drug|Drug,Experimental group|Control group,Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months,2,NA,NA,NA,NA,NA,NA,NA
NCT04329650,"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia,"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",Not yet recruiting,NA,Phase 2,100,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:13:30Z,2020-04-03T09:13:30Z,Drug|Drug,Siltuximab|Methylprednisolone,"A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.|A dose of 250mg/24 hours of methylprednisolone during 3 days followed by 30mg/24 hours during 3 days will be administered by intravenous infusion.
If the patient is taken lopinavir/ritonavir, the dose will be 125 mg/ 24 hours during 3 days followed by 15mg/24 hours during 3 days.",2,,Hospital ClÃ­nic de Barcelona,Barcelona,,08036,Spain,1
NCT04331834,"ClinicalTrials.gov processed this data on April 02, 2020",2020-04-01,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 3, 2020",Anticipated,2020-04-03,April 2020,2020-04-30,"October 30, 2020",Anticipated,2020-10-30,"October 3, 2020",Anticipated,2020-10-03,NA,Interventional,PrEP_COVID,,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial",Not yet recruiting,NA,Phase 3,440,Anticipated,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:13Z,2020-04-03T09:12:13Z,Drug|Drug,Hydroxychloroquine|Placebos,"Hydroxychloroquine with the following dosage:
day 0: 400 mg (2 tablets)
day 1: 400 mg (2 tablets)
day 2: 400 mg (2 tablets)
day 3: 400 mg (2 tablets)
weekly: 400 mg (2 tablets) for a period of six months|Placebo with the following dosage:
day 0: 400 mg (2 tablets)
day 1: 400 mg (2 tablets)
day 2: 400 mg (2 tablets)
day 3: 400 mg (2 tablets)
weekly: 400 mg (2 tablets) for a period of six months",2,,ISGlobal,Barcelona,,08036,Spain,1
NCT04331795,"ClinicalTrials.gov processed this data on April 02, 2020",2020-04-01,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 3, 2020",Anticipated,2020-04-03,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,COVIDOSE,,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Not yet recruiting,NA,Phase 2,50,Anticipated,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:15Z,2020-04-03T09:12:15Z,Drug|Drug,Tocilizumab|Tocilizumab,"Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.
Second dose is provisioned if evidence of clinical worsening or lack of C-reactive protein response.|Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.
Second dose is provisioned if evidence of clinical worsening or lack of C-reactive protein response.",2,,University of Chicago Medicine,Chicago,Illinois,60637,United States,1
NCT04331665,"ClinicalTrials.gov processed this data on April 02, 2020",2020-04-01,NA,NA,2020-04-01,2020-04-01,2020-04-02,Estimate,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Estimate,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"January 31, 2021",Anticipated,2021-01-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,,Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia,Not yet recruiting,NA,N/A,64,Anticipated,"University Health Network, Toronto",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-03T09:12:19Z,2020-04-03T09:12:19Z,Drug,Ruxolitinib,"Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.",1,,Princess Margaret Cancer Centre,Toronto,Ontario,M5G 2M9,Canada,1
